thesis mdt - copy
TRANSCRIPT
“DEVELOPMENT OF RAPIDLY DISINTEGRATING TABLETS FOR A
MODEL ANTI-EMETIC DRUG.”
By
SREENIVASA REDDY. N
Dissertation submitted to The Rajiv Gandhi University of Health Sciences,
Karnataka
In partial fulfillment of the requirements for the degree of
Master of Pharmacy in
Pharmaceutics
Under the guidance of
Dr.M.S Srinath
Department Of Pharmaceutics Government College Of Pharmacy.
No. 2, P. Kalinga Rao Road, Bangalore - 560027
January 2005
ACKNOWLEDGEMENT
In the name of God and my Guru, I bow myself to thank and acknowledge the
continued blessings showered on me to successfully complete my dissertation. I am deeply indebted to express my wholehearted gratitude and thanks to my
beloved mother, Smt. Sarojanamma, father Sri.Hanumantha Reddy and to whom I owe in a substantial measure in the successful completion of this subject.
It gives me immense pleasure to acknowledge, the help rendered to me by a host
of people, to whom I owe gratitude for the successful completion of my M.Pharm. The research work embodied in this dissertation has been carried out under the
supervision of my esteemed and most respected Guide, Head, Dept. of Pharmaceutics and Principal Prof.Dr.M.S. Srinath, Government College of Pharmacy, Bangalore. I take this golden opportunity to thank and express my sincere gratitude for his continuous encouragement, valuable suggestions, dynamic guidance, ever readiness to solve my problems, moral support and blessings shown on me throughout the period of this work.
I thank Assistant Professor Dr. N.G. Nanjunda swamy and lecturer Smt. B.P Manjula Dept., of Pharmaceutics, for their concern, cooperation and encouragement throughout the duration of the course.
I thank beloved and respected Prof. M.S.Harish, Head, Dept.of Pharmacology,
for his wholehearted concern, care and encouragement throughout the duration of the course.
I thank Assistant Professor Sri M. S. Niranjan, Sri Chandrashekar Javali
lecturer, Dept. of Pharmaceutical Chemistry, Govt. College of Pharmacy, Bangalore, for their encouragement and help.
I thank Dr. Shashidhara, Assistant Professor, Dept. of Pharmacognosy, for his
encouragement and moral support.
My regards to Prof. M. Lakshmana, Retd.-Principal of GCP, B’lore for his encouragement and support. And my regards to Dr. M. D. Karvekar for his care and encouragement. My special thanks to Asst. Professor Sri. Nagaraj, Sri. V. Ramakrishna and Sri Kalaskar, Lecturer, Govt. College of Pharmacy, Bangalore, for their encouragement and help. And my regards to Sri. Sathish, Sri Mukund, lecturers for their affection.
I would like to express my sincere and heartfelt thanks to Sri. C. Narendra,
Lecturer, Krupanidhi College of Pharmacy, Bangalore, for his kind help and sparing his precious time in carrying out the process of optimization.
i
I also acknowledge with heartfelt thanks M/s KAPL, Bangalore and
M/s EROS Pharma, Bangalore and M/s Ce-Chem Pharma, Bangalore for providing various excipients required for my work.
I thank Prof. Gopala Krishna Rao and Prof. Sanjay Pai, Dept. of Pharmachemistry, Al-Ameen College of Pharmacy, for their encouragement.
I take this opportunity to thank all the teaching and non-teaching staff Sri.
Prabhakar, Sri.LakshmiNagesh, SriNageshachar, SriThippeswamy, Smt.Veena and Librarians Smt.. B.K. Rohini and Smt. P. Aruna Sanjeeva Rao of Govt. College of Pharmacy, Bangalore, for their constant support and help.
At this juncture I would be failing, if I do not acknowledge the help of
Sri R. Chandrashekar., Chief Pharmacist, , Govt. Medical Stores, Bangalore, who was my moral and guiding supporter for my higher education.
I thank the Director and all the officials of Health Department, specially
Sri Dalappa, Sri Sreedhar, Sri Gopal and Sri Gopal reddy of DME for their timely support in permitting me to pursue M. Pharm.
My sincere thanks to Sri Nagaraj, Sri Ittagi (section Officers),
Sri Chandrappa, Sri Putnanjayya, Sri Shivalingaiah of Health Secretariat, M.S. Buildings, Bangalore for getting me permission to study M. Pharm.
I thank with highest regards to honorable Sri G. H. ThippaReddy, Sri Shankara
Reddy, Sri N. Surya Narayana Reddy, Members of Legislative Assembly, Sri G. Madhusudan, Member of Legislative Council and Sri K. Basavana Goud, Member of Parliament for their valuable support and help as always.
I thank my brothers Sri Basavaraj, Sri Gopal Reddy and my brother in law
Sri Gurudas Reddy, Sri Satishwar Reddy and their family members for their encouragement and support.
I sincerely acknowledge the special affection and moral support rendered by my brother-in-law Sri. C. S. Reddy and my sister Smt. Geetha all throughout my career in all the ways.
My sincere thanks to cousins specially Sri Anantha Reddy and Sri Nagaraj
Reddy for their valuable support in each and every movement. Mere words and acknowledgement cannot express the valuable help and
encouragement rendered by my friends specially Mr. Nataraj and Ms. Sindhu during my course and the kind help rendered by Mr.Prakash, Mr.Satish, Ms.Jayanthi, Mr.Satya, Mr.Somashekar, Mr.Vadivelan, Mr.Mahantesh, Mr.Suresh, Mr.Prathap,
ii
Mr.Ragavendra, Mr.Shreekant, Ms.Anusha, Ms.Malini, Ms.Nazia and Ms.Shameem.
I thank my seniors Mrs.Anitha, Mr.Siddu, Mr.Afrasim Moin, Mr.Sreenivasa Reddy, Mrs.Girija, Mr.Neelkant, Mr.Shalam, Mr.Badri, Mr.Harish, Mr.Suhas and Ms.Priya and others for their guidance and help.
I thank my juniors especially Mr.Rajesh and Mr.Sachin who were remembered for their support and help, during my course. I also thank Mr.Doddamani Mr.Nagesh, Ms.Vijaya, Mr.Pasha, Mr.Vathan, Mr.Ismail, Mr.Zarnappa, Mr.Naveen, Mr.Nagaraj, Ms.Aswini, Ms.Jaysheela, Mr.Ananth, Mr.Anne Gowda, Mr.Vageesh and Mr.Shabuddin for their kind support and help.
I remember at this juncture the cooperation rendered by my well wishers Sri. Suresh Shetty, Sri. Kalidas, Sri. Shantaram Shetty, Sri. Gurudev, Sri.Naganna and Sri. Rajiv for their moral support.
I also thank Mr. Arvind and Miss. Shweta of Cyber Arcade, Jayanagar in
designing and printing of my Research work. I am pleased to express my sincere thanks to my wife Smt. Prasanna Lakshmi
for her kind, heartfelt and moral support during my entire course, which cannot be expressed in mere words. With out her kind cooperation and sacrifice, it would have been impossible for me to complete my research project. I am happy that my son Master Srujan co-operated with me during my project work.
Finally, I take this opportunity to express my gratitude to all the people involved
directly or indirectly in the successful completion of this dissertation work. Date: Place: Bangalore (N. SREENIVASA REDDY)
iii
iv
LIST OF ABBREVIATIONS USED Abs. : Absorbance
BP : British Pharmacoepia
CDR : Cumulative drug release
CLA : Cumulative loss account
Conc. : Concentration
CPVP : Crospovidone
DCP : Dicalcium Phosphate dihydrate
DT : Disintegration time
GIT : Gastro intestinal tract
g : gram
Hrs : Hours
HCl : Hydrochloric acid
HPC : Hydroxypropyl Cellulose
IP : Indian Pharmacoepia
IR : Infrared
mg : milligram
ml : milliliter
mm : millimeter
µg : microgram
µ l : microlitre
nm : nanometer
PA : Physical Appearance
%DC : Percentage Drug content
pH : Hydrogen ion concentration
ppm : parts per million
PVP : Poly Vinyl Pyrrolidone
Rf : Retention / resolution factor
RH : Relative Humidity
rpm : revolutions per minute
SEM : Standard error of mean
SSG : Sodium starch Glycolate
TLC : Thin Layer Chromatography
USP : United States Pharmacoepia
UV : Ultra Violet
Wt. : Weight
WT : Wetting Time
ABSTRACT
“DEVELOPMENT OF RAPIDLY DISINTEGRATING TABLETS FOR A MODEL
ANTI-EMETIC DRUG”
Sreenivasa Reddy N., Dr. M. S. Srinath, Government College of Pharmacy, Bangalore.
The present research work is an attempt to formulate and evaluate rapidly disintegrating tablets
of a model anti-emetic drug, Metoclopramide Hydrochloride prepared by direct compression
method.
The drug excipient compatibility studies were carried out. The tablets were formulated
by direct compression method, using directly compressible Mannitol, Dicalcium phosphate and
Avicel PH 200 as diluents. Crospovidone (5, 7.5, 10%), Crosscarmellose sodium (5, 7.5, 10%),
Low substituted hydroxy propyl cellulose (5, 7.5, 10%) and Sodium starch glycolate (10, 12.5,
15%) were used as disintegrants at different concentrations. Pregelatinized starch was used as a
binder in all the formulations to attain hardness. Aspartame was used as the sweetening agent.
The pre compression parameters like bulk density, tapped density, Carr’s Index and angle
of repose were determined. The post compression parameters like the hardness, thickness,
friability, weight variation, Disintegration time as per IP, wetting time and disintegrating time in
oral cavity for all the formulations were carried out. Crospovidone and Sodium starch glycolate
exhibited quicker disintegration of tablets than compared to those of Low substituted Hydroxy
propyl cellulose and Crosscarmellose sodium.
A 32 full factorial design was performed to study the effect of the formulation variables
on the DT and WT. Factors X2 (CPVP) were found to be significant for WT and factor X1 (SSG)
were found to be significant for DT. Interaction factors were found to be big for both the
responses. A numerical optimization was performed to find the optimum composition of RDT
and based on this an optimized formulation was arrived containing 5.13 mg of Sodium Starch
Glycolate and 12.5 mg of Crospovidone.
Finally it is concluded that the so developed formula holds good for Metoclopramide
Hydrochloride where rapid action is desired.
Keywords: Optimization; Disintegration; Metoclopramide Hydrochloride; Compression;
Hardness; Microcrystalline cellulose; Low- substituted hydroxy propyl cellulose.
TABLE OF CONTENTS
Chapter No. Title Page No.
1 Introduction 1
2 Objectives 14
3 Review of Literature 16
4 Methodology 38
5 Results 67
6 Discussion 100
7 Conclusion 109
8 Summary 110
9 Bibliography 112
iv
LIST OF TABLES
Sl.No Title
Page No.
1 Calibration curve of Metoclopramide Hydrochloride in 0.1N HCl. 45
2 Drug – Excipient compatibility studies- Rf values 48
3 Actual and coded values of factors 51
4 Runs designed in Actual and coded values 52
5 Dicalcium Phosphate based tablet formulations 53
6 Mannitol based tablet formulations 54
7 Avicel PH 200 based tablet formulations 55
8 Tablet formulations as per DOE 56
9 Carr’s index values 59
10 Pre-compression parameters of DCP formulations 67
11 Post- compression parameters of DCP formulations 67
12 Comparison between DT, DTO and WT. 68
13 Invitro release profile of DCP formulations at 5minutes 70
14 Invitro release profile of DCP formulations at 20 minutes 70
15 Pre-compression parameters of Mannitol formulations 72
16 Post- compression parameters of Mannitol formulations 72
17 Comparison between DT, DTO and WT. 73
18 Invitro release profile of Mannitol formulations at 5minutes 75
v
Sl.No Title
Page No.
19 Invitro release profile of Mannitol formulations at 20 minutes 75
20 Pre-compression parameters of Avicel PH 200 formulations 77
21 Post- compression parameters of Avicel PH 200 formulations 77
22 Comparison between DT, DTO and WT. 78
23 Invitro release profile of Avicel PH 200 formulations at 5minutes 80
24 Invitro release profile of Avicel PH 200 formulations at 20 minutes 80
25 Design and summary response data 83
26 ANOVA cubic model 84
27 Estimated regression coefficient 84
28 ANOVA Response Surface Cubic Model (Aliased) 86
29 Estimated regression coefficient 86
30 Optimized formula 89
31 Predicted solution of optimized formula 89
32 Pre-compression parameters of runs as per DOE 90
33 Post- compression parameters of runs as per DOE 90
34 Comparison between DT, DTO and WT. 91
35 Invitro release profile of runs as per DOE at 5minutes 93
36 Invitro release profile of runs as per DOE formulations at 20 minutes 93
37 Composition of optimized formulation 96
38 Pre-compression parameters of optimized formula 96
vi
Sl.No Title
Page No.
39 Post- compression parameters of optimized formula 96
40 Comparison between DT, DTO and WT. 97
41 Invitro release profile of optimized formula 97
42 Stability data of optimized formula stored at 25oC / 60% RH 99
43 Stability data of optimized formula stored at 40oC / 75% RH 99
44 Comparison of Precompression parameters of all the formulations 101
45 Comparison of Hardness of all the formulations 102
46 Comparison chart of predicted and actual values for optimized formulation 108
vii
LIST OF FIGURES
Sl.No Title
Page No.
1 IR spectrum of Metoclopramide Hydrochloride 42
2 UV spectrum of Metoclopramide Hydrochloride 43
3 Calibration curve of Metoclopramide Hydrochloride in 0.1N HCl 45
4 Schematic representation of Drug – excipient compatibility studies 46
5 TLC photograph of drug- Excipient compatibility studies. 49
6 Disintegration profile of DCP formulations 69
7 Dissolution profile of DCP formulations 71
8 Disintegration profile of Mannitol formulations 74
9 Dissolution profile of Mannitol formulations 76
10 Disintegration profile of Avicel PH 200 formulations 79
11 Dissolution profile of Avicel PH 200 formulations 81
12 Perturbation plot showing effect of Concentration of SSG on wetting time. 85
13 Perturbation plot showing effect of Concentration of CPVP on wetting time. 85
14 3-D graph showing combined effect of SSG and CPVP on wetting time 85
15 Perturbation plot showing effect of Concentration of SSG on DT 88
16 Perturbation plot showing effect of Concentration of CPVP on DT 88
17 3-D graph showing combined effect of SSG and CPVP on DT 88
18 Disintegration profile of runs as per DOE 92
19 Dissolution profile of runs as per DOE 95
20 Dissolution profile of optimized formula 98
21. Figure depicting Wetting time of Optimized formulation 98 a.
viii
Introduction
INTRODUCTION
RAPIDLY DISINTEGRATING TABLETS 1
Among the different routes of administration, the oral route of administration
continues to be the most preferred route due to various advantages including ease of
ingestion, avoidance of pain, versatility and most importantly patient compliance. The
different dosage forms include tablets and capsules. The important drawback of these
dosage forms for pediatric and geriatric patients is being difficulty in swallowing.
Nearly 35% of the general population, especially the elderly patients and children
suffer from Dysphagia or difficulty in swallowing, which results in high incidence of
noncompliance and ineffective therapy. Swallowing problems also are very common in
young individuals because of their poorly developed muscular and nervous systems.
Other groups who may experience problems in swallowing conventional oral dosage
forms are the patients with tremors of extremities, mentally ill, developmentally disabled,
non co-operative patients and patients with reduced liquid intake plans or patients
suffering from nausea. The swallowing problems are also common in some cases such as
patients with motion sickness, sudden episodes of allergic attack or coughing and due to
lack of water.
To overcome these problems, formulators have considerably dedicated their effort
to develop a novel type of tablet dosage form for oral administration, i.e., one, which
disintegrates and dissolves rapidly in saliva without the need for drinking water. The
tablet is placed in the mouth, allowed to disperse or dissolve in the saliva. These tablets
Department of Pharmaceutics, GCP, B’lore-27.
1
Introduction usually dissolve within 15 seconds to 2 minutes. The faster the drug goes into solution,
the quicker the absorption and onset of clinical effect.
Less frequently, they are designed to be absorbed through the buccal and oesophageal
mucosa as the saliva passes into the stomach. In the latter case, the bioavailability of a
drug from rapidly disintegrating tablets may be even greater than that observed for other
standard dosage forms.
The rapidly disintegrating tablets also offer advantages over other oral dosage forms
such as effervescent tablets, suspensions, chewing gum or chewing tablets, which are
commonly used to enhance patient compliance. Effervescent tablets and suspensions
require preparatory steps before administration of the drug. The elderly, who often are
unable to chew large pieces of gum or tablets, sometimes experience unpleasant taste
when bitter drugs are consumed.
The advantages of rapidly disintegrating tablets are being recognized in both
industry and academia. Their growing importance was underlined recently when the
European Pharmacopoeia adopted the term Orodispersible tablet as a “tablet to be placed
in the mouth where it disperses rapidly before swallowing”.
The ideal rapidly disintegrating tablet technology should address the following:
Requires no water for oral administration, yet dissolve or disintegrate in the
mouth in a matter of seconds.
Allow high drug loading.
Bitter taste to be masked.
Have a pleasant mouth feel.
Leave minimal or no residue in the mouth after oral administration.
Department of Pharmaceutics, GCP, B’lore-27.
2
Introduction
Be portable without fragility concerns.
Exhibit low sensitivity to environmental conditions such as humidity and
temperature.
Allows the manufacture of tablets using conventional processing and packaging
equipment at low costs.
The techniques used in the preparation of rapidly disintegrating tablets are: -
CONVENTIONAL TECHNIQUES 1, 2
1. Tablet molding:
In this method, the delivery system is prepared in the form of tablets using water-
soluble additives, to allow the tablets to dissolve rapidly and completely in mouth.
All the ingredients of the formulation are passed through fine mesh, dry blended,
wetted with a hydro-alcoholic solvent and then compressed into tablets using low
compression forces.
2. Freeze drying (Lyophilization):
Lyophilization is a pharmaceutical manufacturing technology, which allows
drying of heat sensitive drugs and biologicals at low temperatures under conditions
that allow removal of water by sublimation. Lyophilization results in preparations,
which are highly porous, with a very high specific surface area, which dissolve
rapidly and show improved absorption and bioavailability.
Department of Pharmaceutics, GCP, B’lore-27.
3
Introduction 3. Spray drying:
Spray drying is a process by which highly porous, fine powders can be produced.
The composition contains a bulking agent (e.g. mannitol and lactose), a disintegrant
(e.g. sodium starch glycollate and croscarmellose sodium), an acidic ingredient (citric
acid) and/or alkaline ingredients (e.g. sodium bicarbonate) which when compressed
into tablets shows fast disintegration and enhanced dissolution.
4. Sublimation:
This method includes the addition of a sublime salt to the tableting components,
compressing the blend and removing the salt by the process of sublimation. The
active ingredient, a diluent, a sublime salt (ammonium carbonate, ammonium
bicarbonate), a binder and other excipients are blended and tablets are prepared.
5. Addition of Disintegrants:
Addition of disintegrants in fast dissolving tablets, leads to quick disintegration of
tablets and hence improves dissolution. Microcrystalline cellulose, cross-linked
Carboxymethylcellulose Sodium, cross-linked polyvinyl pyrrolidone and partially
substituted Hydroxypropyl cellulose, absorb water and swell due to capillary action
and are considered as effective disintegrants in the preparation of fast dissolving
tablets.
Department of Pharmaceutics, GCP, B’lore-27.
4
Introduction 6. Sugar-based excipient:
Sorbitol, mannitol, dextrose, xylitol, fructose, maltose, isomalt, and polydextrose
have been used as bulking agents. Because of their high aqueous solubility and
sweetness, which impart a pleasing mouth feel and good taste masking, nearly all
formulations for rapidly dissolving tablets contain sugar-based materials.
PATENTED TECHNOLOGIES:
7. ZYDIS
This technology converts the mixture of active ingredient and water dispersible
carrier materials into open matrix network that disintegrates rapidly using freeze-
drying process. The network is highly porous solid foam, which allows rapid
penetration of liquid and facilitates quick disintegration of the dosage unit. In Zydis
technology, drug is added to a solution of carrier material (preferably gelatin) to
obtain dispersion, and the dispersion is filled into preformed pockets of blister pack
by automatic means, and freeze dried to produce the final dosage form.
8. ORASOLV
This system essentially makes tablets that contain the taste masked active
ingredients and an effervescent disintegrating agent, which on contact with saliva,
rapidly disintegrates and released the active ingredient. The tablets are made by
direct compression at very low compression forces in order to minimize oral
dissolution time. The tablets produced are soft and friable.
Department of Pharmaceutics, GCP, B’lore-27.
5
Introduction 9. DURASOLV
The tablet made by this technology consists of a drug, fillers and a lubricant.
DuraSolv tablets are prepared by using conventionally tableting equipment and have
good rigidity. It is an appropriate technology for products requiring low amounts of
active ingredients.
10. FLASH DOSE
Flash dose tablets consists of self-binding shear form matrix termed as “floss”.
Shear form matrices are prepared by flash heat processing and are of two types.
Single floss or Unifloss, consisting of a carrier, and two or more sugar alcohols,
of which one is xylitol.
Dual floss consists of a first shear form carrier material (termed “base floss”,
contains a carrier and at least one sugar alcohol generally sorbitol), and a second
shear form binder matrix (“binder floss”, contains a carrier and xylitol).
In flash heat process, the feed stock (carbohydrates including sugars and
polysaccharides) is simultaneously subjected to centrifugal force and to a temperature
gradient, resulting in discrete fibers. The preformed matrices obtained are partially
crystallized and have good self-binding and flow properties. The so formed matrices
are complex crystalline structures with high specific surface area and result in rapid
dissolution rate of the drug. The shear form matrix is blended with drug and other
tableting ingredients, and compressed into tablets using conventional tableting
equipment. Flash dose tablets are soft, friable and hygroscopic dosage forms, which
require specialized packaging.
Department of Pharmaceutics, GCP, B’lore-27.
6
Introduction 11. WOW TAB
This process uses a combination of low mouldability saccharide (rapid
dissolution) and high mouldability saccharide (good binding property) to obtain a
rapidly melting strong tablet. The active ingredient is mixed with a low mouldability
saccharide (e.g. lactose, mannitol) and granulated with a high mouldability saccharide
(e.g. maltose, sorbitol) and compressed into tablets.
12. FLASHTAB
This technology involves the preparation of rapidly disintegrating tablet, which
consists of an active ingredient in the form of micro crystals. Drug micro granules
may be prepared by using the conventional techniques like coacervation; micro
encapsulation; extrusion-spheronization or simple pan coating method. The micro
crystals or micro granules of the active ingredient are added to the granulated mixture
of excipients prepared by wet or dry granulation, and compressed into tablets.
DIRECT COMPRESSION METHOD 3
Direct compression is the easiest method to manufacture rapidly disintegrating
tablets (RDTs) and fast-melting tablets (FMTs). The great advantage of direct
compression is its low manufacturing cost. It uses conventional equipment, commonly
available excipients and a limited number of processing steps.
In many cases the disintegrants used have a major role in the disintegration and
dissolution process of rapidly disintegrating tablets made by direct compression method.
Department of Pharmaceutics, GCP, B’lore-27.
7
Introduction The choice of a suitable type and an optimal amount of disintegrant is important for
ensuring a high disintegration rate. The addition of other formulation components such
as water-soluble excipients or effervescent agents can further enhance dissolution or
disintegration properties.
The understanding of disintegrant properties and their effect on formulation has
advanced significantly during the last few years, particularly regarding so called super-
disintegrants.
Caramella et al3 found that disintegration efficiency is based on the force-equivalent
concept (the combined measurement of swelling force development and amount of water
absorption). Force equivalence expresses the capability of force. The optimization of
tablet disintegration was defined by means of the disintegrant critical concentration.
Below this concentration, the tablet disintegration time is inversely proportional to the
disintegrant concentration. Above the critical concentration, the disintegration time
remains approximately constant or even increases.
OPTIMIZATION 4,5
The word optimize is defined as, to make as perfect, effective or functional as
possible. Optimization may be interpreted as to find out the values of controllable
independent variables, that gives the most desired value of dependent variables.
In the trial and error method, a lot of formulations have to be prepared to get a
conclusion, which involves lot of money, time and energy. These can be minimized by
the use of optimization technique.
Department of Pharmaceutics, GCP, B’lore-27.
8
Introduction Optimization process:
Generally optimization process involves the following steps.
1. Based on the previous knowledge or experience or from literature, the
independent variables are determined or set in the beginning.
2. Selection of a model based on the results of the factor screening.
3. The experiments are designed and are conducted.
4. The responses are analyzed by ANOVA, test on lack of fit, to get an empirical
mathematical model for each individual response.
5. The responses are screened by using multiple criteria to get the values of
independent variables.
Experimental design6
Experimental design is a statistical design that prescribes or advises a set of
combination of variables. The number and layout of these design points within the
experimental region, depends on the number of effects that must be estimated.
Depending on the number of factors, their levels, possible interactions and order of the
model, various experimental designs are chosen. Each experiment can be represented as
a point within the experimental domain, the point being defined by its co-ordinate (the
value given to the variables) in the space.
Department of Pharmaceutics, GCP, B’lore-27.
9
Introduction a) Factorial design
It is an experimental design, which uses dimensional factor space at the corner of
the design space. Factorial designs are used in experiments where the effects of different
factors or conditions on experimental results are to be elucidated. These are the design of
choice for simultaneous determination of the effect of several factors and their
interaction.
The simplest factorial design is the two-factorial design where two factors are
considered each at two levels, leads to four experiments, which are situated in 2-
dimensional factor space at the corners of a rectangle. If there are three factors, each at
two levels, eight experiments are necessary which are situated at the corners of an
orthogonal cube in a 3-dimensional space. The number of experiments is given by 2n,
where ‘n’ is the number of factors.
If the number of factors and levels are large, then the number of experiments
needed to complete a factorial design is large. To reduce the number of experiments,
fractional factorial design can be used (i.e., ½ or ¼ of the original number of experiments
with full factorial design).
The fitting of an empirical polynomial equation to the experimental result
facilitates the optimization procedure. The general polynomial equation is as follows:
Y = B0 + B1X1 + B2X2 + B3X3 +…+ B12X1X2 + B13X1X3 + B23X2X3 +…+ B123X1X3.
Where, Y is the response,
X1, X2, X3 are the levels (concentration) of the 1,2,3 factors
B1, B2, B3, B12, B13, B23, B123, are the polynomial coefficients.
Department of Pharmaceutics, GCP, B’lore-27.
10
Introduction B0 is the intercept (which represents the response when the level of all factors is
low).
b) Plackett – Burman design
It is a special fractional factorial design with K = m*4 experiment, for screening
of (K-1) variables, Where ‘K’ is the number of variables and ‘m’ is the number of
levels.
c) Star design
Star design is simply a 22 factorial design rotated over 450 angle in the space. A
center point is usually added, which may be replicated to estimate the experimental
error, so there will be three levels for each factor where quadratic effect can be
measured, but the interaction effect cannot be measured as that in case of factorial
design. In the star designs, 2k Factorial designs are rotated over 450 in (k-1) direction
in k-dimensional space with a replicated center point. ‘k’ is the number of factors in
the design. This results in 2k + Rc experiments, where Rc is the replicates of the
center point.
d) Central Composite design
A better design that combines the advantages of Factorial design or Fractional
factorial design and the Star design, is the central composite design (CCD) developed
by Box and Wilson. It is composed of
Department of Pharmaceutics, GCP, B’lore-27.
11
Introduction
• 2k Factorial design or 2(k-p) Fractional factorial design.
• 2*k Star design
This design enables the estimation of a full second-order model. The equation for
two factors is given by
E(y) = B0+B1X1+B2X2+B12X1X2+B11X12+B22X2
2
Validation of the model
The model is validated using ANOVA calculation, then the estimation pure
measurement error is done. The variance of these observations pooled over all to get an
estimate of pure error of variance. The F-test on regression and lack of fit will be useful
for judging descriptive properties of a model and the significance of model terms.
Predictions using the selected model
Once a model is selected and validated, the brute force method is applied for the
prediction of response. With the help of 3D-response surface or a 2D contour diagram,
the prediction is done using these graphs either by grid search or feasibility search
methods.
Department of Pharmaceutics, GCP, B’lore-27.
12
Introduction Software for designs and Optimization
Many commercial software packages are available which are either dedicated to
experimental design alone or are of a more general statistical type.
Software’s dedicated to experimental designs
Design Ease and Design Expert (Stat-ease)
ECHIP
CARD
Multisimplex
Software for general statistical nature includes
SAS
MINITAB
SYSTAT, etc.
Department of Pharmaceutics, GCP, B’lore-27.
13
Objectives
OBJECTIVE
Nausea and vomiting may be manifestations of a wide variety of conditions,
including pregnancy, motion sickness, gastrointestinal obstruction, peptic ulcer, drug
toxicity, myocardial infraction, renal failure and hepatitis. In cancer chemotherapy, drug
induced nausea and vomiting may occur so regularly that anticipatory vomiting occurs
when patients return for treatment before the chemotherapeutic agent is given. If not
controlled, the discomfort associated with drug – induced emesis may cause a patient to
refuse further chemotherapy.
Conventional tablets are available to treat nausea and vomiting, but swallowing
problems are common to 35% of population including patients suffering from
parkinsonism, head and neck surgery, motion sickness etc.
Metoclopramide hydrochloride is a substituted benzamide used for its prokinetic
and anti emetic properties. The drug is very useful in treating nausea and vomiting of
varied etiology, e.g. Nausea and vomiting associated with gastrointestinal disorders,
radiation sickness, hepatobiliary disorders, pre and postoperative periods and migraine.
Hence there is a need to develop rapidly disintegrating tablets, which disintegrates
in matter of seconds in the oral cavity, thereby reducing the time of onset of
pharmacological action.
The study was intended to select the best possible diluent - disintegrant combination
to formulate rapidly disintegrating tablets among the various diluents and disintegrants
used. Direct compression method was employed to formulate the tablets, because of its
cost effectiveness and due to reduced number of manufacturing steps.
Department of Pharmaceutics, GCP, B’lore-27.
14
Objectives
PLAN OF WORK:
1. Screening of various disintegrating agents for the preparation of rapidly
disintegrating tablets.
2. Formulation of rapidly disintegrating tablets by using different diluents,
disintegrants and other excipients.
3. Best disintegrating agents was further evaluated by using design of
experimental technique (DOE).
4. The results were subjected to ANOVA for the development of polynomial
models.
5. The best formulation was selected based on numerical optimization.
6. To study the Drug- Excipient compatibility.
7. Stability studies for the selected formulations.
Department of Pharmaceutics, GCP, B’lore-27.
15
Review of Literature
REVIEW OF LITERATURE
2.1 DRUG DATA 7
METOCLOPRAMIDE HYDROCHLORIDE Metoclopramide hydrochloride is a substituted benzamide used for its prokinetic and anti
emetic properties. It stimulates the motility of the upper gastrointestinal tract without
affecting gastric, biliary or pancreatic secretion and increases gastric peristalsis leading to
accelerated gastric emptying.
CHEMISTRY
Metoclopramide is a chlorobenzamide derivative chemically known as 4-amino-5-chloro-
N-(2-diethylaminoethyl)-2-methoxybenzamide hydrochloride monohydrate.
The structure is shown below:
Department of Pharmaceutics, GCP, Bangalore -27.
16
Review of Literature
PHARMACOLOGY
The principle Pharmacological effects of Metocopramide Hydrochloride involve
the GI tract and CNS. Although structurally similar to Procainamide, Metoclopramide
HCl lacks significant local anesthetic activity.
The drug is a substituted benzamide, which stimulates the motility of upper GI
tract without affecting gastric acid secretion. It increases gastric peristalsis leading to
accelerated gastric emptying. Duodenal peristalsis is also increased which decreases
intestinal transit time.
It possesses parasympathomimetic activity as well as being a dopamine receptor
antagonist with a direct effect on CTZ has anti- emetic effect.
Mechanism of action:
Metoclopramide hydrochloride acts:
1) By blocking Dopamine receptors of Chemoreceptor Trigger Zone (CTZ).
2) By increasing frequency and depth of antral contractions and regularizing motility
between antrum and duodenal bulb, thus facilitating gastric emptying due to
dopaminergic receptor blockade, potentiation of cholinergic, muscarinic effects
and direct action on the smooth muscle
3) By blocking 5-HT receptors of CTZ, at higher concentrations.
Department of Pharmaceutics, GCP, Bangalore -27.
17
Review of Literature
PHARMACOKINETICS
Absorption:
Metoclopramide HCl is rapidly and completely absorbed after oral administration,
but hepatic first metabolism reduces its bioavailability to 75%.
Following oral administration of a single 10mg dose of the drug, peak plasma
Metoclopramide concentrations of 32-44ng/ml occurred at 1-2 hours. The onset of
Pharmacological actions of the drug on the GI tract is 1-3 minutes following i.v
administration, 10-15 minutes following i.m administration and 30 - 60minutes following
oral administration.
Distribution
Apparent volume of distribution of Metoclopramide Hydrochloride is 2.2 - 3.4
liters/ kg in adults. The drug crosses the Blood brain barrier and placenta. It is weakly
bound to plasma proteins.
Elimination
Elimination half life (t 1/2) is 4-6 hours. The t 1/2 is prolonged in patients with renal
failure. It is excreted in urine, about 85% of a dose being eliminated in 72 hours, 20-30%
as unchanged Metoclopramide and the remainders as sulfate or glucuronide conjugate.
About 5% of a dose is excreted in faeces via the bile.
Department of Pharmaceutics, GCP, Bangalore -27.
18
Review of Literature
INDICATIONS
Metoclopramide hydrochloride is used:
In disorders of decreased gastrointestinal motility such as gastorparesis or ileus.
In gastro –esophageal reflux disease.
In dyspepsia
To stimulate gastric emptying during radiographic examinations.
Parenterally in high doses for prevention of nausea and vomiting associated with
cancer therapy (Cisplatin induced).
Parenterally to facilitate intubation of small intestine in adults and children in
whom the tube (endoscope) does not pass through the pylorus with conventional
maneuver.
For the short term (upto 12 weeks) relief of symptomatic, documented gastro
esophageal reflux in adults who are not responding to conventional therapy alone.
Parenterally for the prevention of postoperative nausea and vomiting.
In the treatment of migraine to alleviate nausea and vomiting and gastric stasis.
CONTRAINDICATIONS
Recent GI surgery
Gastrointestinal hemorrhage, obstruction or perforation.
Drug intolerance
Pheochromocytoma (tumor of the adrenal medullary cells).
Tardive dyskinesia
Epilepsy
Department of Pharmaceutics, GCP, Bangalore -27.
19
Review of Literature
DOSING INFORMATION
1. For the relief of Symptomatic Gastroesophageal reflux: 10mg to 15mg orally
upto four divided doses, 30 minutes before each meal and at bedtime.
2. For the relief of symptoms associated with Diabetic gastorparesis: 10mg of
Metoclopramide 30 minutes before each meal and at bedtime for two to eight
weeks.
3. For the prevention of nausea and vomiting associated with emetogenic
Cancer chemotherapy: I.V infusions should be made slowly over a period of not
less than 15 minutes, 30 minutes before beginning cancer chemotherapy and
repeated every 2 hours for two doses, then every 3 hours for three doses.
4. To facilitate Small bowel intubation:
Patients of age 14 years and adults - 10mg of Metoclopramide base
6- 14 years of age - 2.5 to 5mg of Metoclopramide base
Under 6years - 0.1mg / kg of Metoclopramide base
ADVERSE EFFECTS
Metoclopramide is a Dopamine antagonist and may cause extra pyramidal
symptoms, which usually occur in acute dystonic reactions; these are more common in
children and young adults, especially if female and at daily doses above 500mcg per kg
body weight. Parkinsonism and tardive dyskinesia have occasionally occurred, usually
during prolonged treatment in elderly patients.
Department of Pharmaceutics, GCP, Bangalore -27.
20
Review of Literature
Other adverse effects include restlessness, drowsiness and diarrhoea, hypotension.
Hypertension, dizziness, headache and depression may occur and there are isolated
reports of blood disorders, hypersensitivity reactions (rash, bronchospasm) and
neuroleptic malignant syndrome.
Metoclopramide stimulates prolactin secretion and may cause galactorrhoea or
related disorders. Transient increases in plasma aldosterone concentartions have been
reported.
Department of Pharmaceutics, GCP, Bangalore -27.
21
Review of Literature
2.2 EXCIPIENT DATA 8
1} Mannitol
Synonyms:
Cordycepic acid, manita, manna sugar, mannite, Pearlitol.
Functional Category:
Tablet and capsule diluent, sweetening agent, tonicity agent, vehicle (bulking agent) for
lyophilized preparations.
Applications:
As a diluent in tablets (10-90% w/w). It is not hygroscopic and can be used with moisture
sensitive active ingredients. In the manufacture chewable tablet formulation because of
its negative heat of solution, sweetness, mouth feel.
Description:
White, odorless, crystalline powder, or free flowing granules. It has a sweet taste.
Solubility:
Freely soluble in water, practically insoluble in ether.
Storage conditions:
The bulk material should be stored in a well-closed container, in a cool, dry, place.
Incompatibilities:
Mannitol solution, 20 % w/v or stronger, may be salted out by potassium or sodium
chloride. It is incompatible with xylitol infusion & may form complexes with metals like
Fe, Al, and Cu.
Safety: When consumed orally in large amounts laxative effects may occur. Daily
ingestion of over 20 g is foreseeable
Department of Pharmaceutics, GCP, Bangalore -27.
22
Review of Literature
2} Dibasic Calcium Phosphate Dihydrate
Synonyms:
Cafos, dicalcium orthophosphate, Di-Cafos, Caltstar, DI-TAB, Emcompress.
Functional category:
Tablet and Capsule diluent.
Applications:
As a diluent in tablets (wet granulation and direct compression). The dihydrate &
anhydrous forms are nonhygroscopic at 250C and relative humidities up to about 90%.
Description:
White odorless, tasteless powder, or crystalline solid.
Solubility:
Practically insoluble in ethanol and water. Soluble in dilute acids.
Storage conditions:
The bulk material should be stored in a well-closed container in a cool, dry, place.
Incompatibilities:
Incompatible with Tetracyclines and Indomethacin. Due to its alkaline nature it should
also not be used with active ingredients that is sensitive to a pH of 7.3 or above.
Safety:
It is generally regarded as a nontoxic and nonirritant material. However, oral ingestion
of large quantities may cause abdominal discomfort
Department of Pharmaceutics, GCP, Bangalore -27.
23
Review of Literature
3} Microcrystalline Cellulose
Synonyms:
Avicel, cellulose gel, crystalline cellulose, E460, Emocel, Fobrocel, Tabulose, Vivacel.
Functional category:
Tablet and Capsule diluent, suspending agent, adsorbent, tablet disintegrant.
Applications:
As a diluent in tablets (wet granulation and direct compression) and capsule formulation.
It also has some lubricant and disintegrant property.
Description:
White-colored, tasteless crystalline powder composed of porous particles.
Solubility:
Slightly soluble in 5 % w/v Sodium hydroxide solution, practically insoluble in water,
dilute acids and most organic solvents.
Stability:
It is a stable, though hygroscopic material.
Storage conditions:
The bulk material should be stored in a well- closed container in a cool, dry, place.
Incompatibilities:
Incompatible with strong oxidizing agents.
Safety:
It is generally regarded as a nontoxic and nonirritant material
Department of Pharmaceutics, GCP, Bangalore -27.
24
Review of Literature
4} Crospovidone
Synonyms:
Cross-linked povidone, Kollidon CL, Polyplasdone XL, PVPP, Polyvinylpolypyrrolidone.
Functional category:
Tablet disintegrant.
Applications:
It is a water insoluble tablet disintegrant used at 2-5 % concentration in tablets,
prepared by wet and dry granulation method.
Description:
White to creamy-white, finely divided, free-flowing, practically tasteless, odorless,
hygroscopic powder.
Solubility:
Practically insoluble in water and most organic solvents.
Stability:
Crospovidone is stable.
Storage conditions:
Since it is hygroscopic it should be stored in an airtight container in a cool, dry, place.
Incompatibilities:
When exposed to a high water level it may form molecular adducts with some materials.
Safety:
It is generally regarded as a nontoxic and nonirritant material.
Department of Pharmaceutics, GCP, Bangalore -27.
25
Review of Literature
5} Croscarmellose Sodium
Synonyms:
Ac-Di-Sol, Cross-linked Carboxymethylcellulose Sodium, Modified Cellulose Gum,
Nymcel ZSX, Primellose, Solutab.
Functional category:
Tablet and Capsule disintegrant.
Applications:
As a disintegrant for tablets (wet granulation and direct compression), capsules and
granules at a concentration of 2- 5%.
Description:
Odorless, white-colored powder.
Solubility:
Insoluble in water, although it swells to 4 to 8 times its original volume on contact with
water.
Stability:
It is a stable though hygroscopic material.
Storage conditions:
It should be stored in a well-closed container in a cool, dry, place.
Incompatibilities:
Efficacy may be slightly reduced in formulations containing hygroscopic excipients
like sorbitol.
Safety: It is generally regarded as a nontoxic and nonirritant material. However,
ingestion of large quantities may have a laxative effect.
Department of Pharmaceutics, GCP, Bangalore -27.
26
Review of Literature
6} Sodium Starch Glycolate
Synonyms:
Carboxymethyl Starch, Explotab, Primogel
Functional category:
Tablet and capsule disintegrant
Applications:
As a disintegrant in tablet (wet granulation and direct compression) and capsules
formulations at a concentration of 2 - 8%.
Description:
White to off-white, odorless, tasteless, free-flowing powder.
Solubility:
Practically insoluble in ether, sparingly soluble in ethanol (95%). In water it swells up to
300 times its volume.
Stability:
It is a stable material.
Storage conditions:
It should be stored in a well-closed container to protect from wide variations in humidity
and temperature that may cause cracking.
Incompatibilities:
Incompatible with ascorbic acid.
Safety:
It is generally regarded as a nontoxic and nonirritant material. However, oral ingestion
of large quantities may be harmful.
Department of Pharmaceutics, GCP, Bangalore -27.
27
Review of Literature
7} Pregelatinized Starch
Synonyms:
Compressible Starch, Instastarch, Lycatab PGS, Sta-Rx 1500, Prejel, Sepistab ST 200.
Functional category:
Tablet and capsule diluent, disintegrant, tablet binder.
Applications:
It is a modified starch used in capsule and tablet formulations as a binder, diluent &
disintegrant
Description:
It occurs as a moderately coarse to fine, white to off-white colored powder. It is odorless
and has a slight characteristic taste.
Solubility:
Practically insoluble in organic solvents. Slightly soluble to soluble in cold water,
depending upon degree of pregelatinization.
Stability:
It is a stable, though hygroscopic material.
Storage conditions:
It should be stored in a well-closed container in a cool, dry, place.
Safety:
It is generally regarded as a nontoxic and nonirritant material. However, oral ingestion
of large quantities may be harmful.
Department of Pharmaceutics, GCP, Bangalore -27.
28
Review of Literature
8} Aspartame
Synonyms:
Aspartyl phenyl amine Methyl Ester, equal, Canderel, Nutrasweet, Sancta, Tri-Sweet.
Functional category:
Sweetening agent.
Applications:
It is used as an intense sweetening agent in tablets powder mixes and vitamin
preparations. It enhances flavor systems, can be used to mask some unpleasant taste, and
has sweetening power of 180-200 times that of sucrose.
Description:
It occurs as white, almost odorless crystalline powder.
Solubility:
Slightly soluble in ethanol (95%), sparingly soluble in water. Solubility increases at
higher temperature and at more acidic pH
Stability:
It is stable in dry conditions. In presence of moisture, hydrolysis occurs. Degradation
also occurs during prolonged heat treatment.
Storage conditions:
Bulk material should be stored in a well- closed container, in a cool, dry, place.
Incompatibilities:
Incompatible with dibasic calcium phosphate & also with magnesium stearate.
Safety:
The WHO has set an acceptable daily intake of 40mg/kg body weight.
Department of Pharmaceutics, GCP, Bangalore -27.
29
Review of Literature
9} Magnesium Stearate
Synonyms:
HyQual, magnesium octadecanoate, stearic acid magnesium salt.
Functional category:
Tablet and capsule lubricant.
Applications:
It is primarily used as a lubricant in capsule and Tablet manufacture at concentrations
between 0.25-5.0%.
Description:
It is a fine, white, precipitated or milled, impalpable powder of low bulk density, having
a faint characteristic odor and taste. The powder is greasy to touch and readily adheres
to the skin.
Solubility:
Practically insoluble in ethanol, ethanol (95%), ether and water, slightly soluble in
benzene and warm ethanol (95%).
Stability:
Magnesium stearate is stable.
Storage conditions:
It should be stored in a well-closed container in a cool, dry, place.
Incompatibilities:
Incompatible with strong acids, alkalis, iron salts and with strong oxidizing materials.
Department of Pharmaceutics, GCP, Bangalore -27.
30
Review of Literature
Safety: It is generally regarded as being nontoxic following oral administration.
However, oral consumption of large quantities may result in some laxative effect or
mucosal irritation.
10} Talc
Synonyms:
Magsil Osmanthus, Magsil Star, Purtalc, Steatite.
Functional category:
Glidant, tablet and capsule lubricant, anti- cackling agent.
Applications:
It is used as a lubricant in solid dosage forms (1-10%), in topical preparations as dusting
powder (90-99 %).
Description:
It is a very fine, white to grayish-white colored, odorless, impalpable, unctuous powder.
It adheres to the skin, is soft to touch, and free from grittiness.
Solubility:
Practically insoluble in dilute acids and alkalies, organic solvents and water.
Stability:
Talc is a stable material.
Storage conditions:
It should be stored in a well-closed container in a cool, dry, place.
Incompatibilities:
Incompatible with quaternary ammonium compounds.
Department of Pharmaceutics, GCP, Bangalore -27.
31
Review of Literature
Safety:
Following oral ingestion talc is not absorbed systemically and may thus be regarded as
an essentially nontoxic material.
Department of Pharmaceutics, GCP, Bangalore -27.
32
Review of Literature
2.3(a) RAPIDLY DISINTEGRATING TABLETS.
1. Yunxia bi et al.,9 have formulated tablets which rapidly disintegrate in the oral cavity
using Microcrystalline cellulose and Low-substituted Hydroxypropyl cellulose as
disintegrants and Ethanzamide and Ascorbic acid as poorly and easily water soluble
model drugs, respectively.
2. Y. X. Bi, H. Sunada, et al.,10 have prepared rapidly disintegrating tablets using
microcrystalline cellulose as diluents, and cross-linked sodium Carboxymethyl cellulose
(Ac-Di-sol) Erythritol are selected as response variables, tablet porosity and parameters
representing the characteristics of formulations were selected as controlling factors and
the relation was determined by the polynomial regression method.
3. Simone Schiermeier, et al.,11 have formulated fast dispersible tablets which disintegrated
either rapidly in water to form a stabilized suspension or disperse instantaneously in the
mouth to be swallowed without the aid of water. They employed a rotatable central
composite design to predict the effects of the quantitative factors, Mannitol and
Crospovidone as well as compression force on the characteristics of the tablet.
4. Hisakadzy Sunada et al.,12 have developed rapidly disintegrating tablets using both direct
compression and wet compression methods. Tablet properties, such as, porosity, tensile
strength, wetting time and disintegrating time were evaluated, and the formulation and
disintegration mechanisms of the tablets were evaluated.
5. Akihiko Ito et al.,13 have developed rapidly disintegrating tablets for elderly patients with
impaired swallowing using agar powders and treated agar powders.
6. Tarasuya Ishikawa et al.,14 have prepared tablets which can rapidly disintegrate in saliva
using taste-masked granules, of drugs with bitter taste (ex. Pirenzepine HCl or
Department of Pharmaceutics, GCP, Bangalore -27.
33
Review of Literature
Oxybutynin HCl). The taste-masked granules were prepared using Eudragit E100 by
extrusion method.
7. Yoshiteru Watanabe et al., 15 have formulated rapidly disintegrating tablets comprising of
crystalline cellulose and low-substituted Hydroxypropyl cellulose (L-HPC).
8. S. Pandey et al.,16 have formulated and optimized fast dissolving tablets of Diclofenac
sodium by direct compression method, using super disintegrants such as cross linked
Carboxy methyl cellulose (Ac-Di-Sol), Sodium starch glycolate (Explotab) and
Crospovidone (Polyplasdone XL) in different concentrations. They reported that tablets
containing Ac-Di-Sol showed better disintegrating character along with rapid release.
9. Chowdary K P R, and Rao Raman N.,17 have carried out formulation and evaluation of
Piroxicam tablets with Piroxicam Pregelatinized Starch dispersions. Dispersions of
Piroxicam in Pregelatinized starch were prepared in different drug and carrier ratios and
were evaluated by X-Ray diffraction, differential thermal analysis and differential
scanning calorimetry studies. They claimed that all the tablets formulated with
Piroxicam-Pregelatinized starch physical mixtures, dispersions were found to contain
Piroxicam within 100 ± 5% of the labeled claim. Thus fast disintegrating tablet giving
rapid dissolution of the drug could be formulated employing Piroxicam Pregelatinized
starch dispersions by conventional wet granulation method
10. KPR Chowdary and Sujatha Rao.,18 have carried out the formulation and evaluation
of dispersible tablets of poorly soluble drugs. Dispersible tablets of three poorly soluble
drugs namely Sulfamethoxazole, Piroxicam and Oxyphenbutazone formulated with
Potato starch and Micro crystalline cellulose fulfilled all the official (BP) requirements
and gave fast and rapid dissolution of the medicament and they reported that the
dissolution followed first order kinetics.
Department of Pharmaceutics, GCP, Bangalore -27.
34
Review of Literature
2.3 (b) ANALYTICAL METHODS FOR ESTIMATION OF METOCLOPRAMIDE
HYDROCHLORIDE.
1. Harish Rao, Aroor AR, et al., 19 have developed a Fluorimetric method for the estimation
of Metoclopramide in pharmaceutical dosage forms.
2. Emmanuel J and Roy Mathew.,20 have carried out colorimetric estimation of
Metoclopramide Hydrochloride in pharmaceutical formulations. Metoclopramide after
diazotisation is coupled with Phloroglucinol, which shows maximum absorbance at 420
nm.
3. Bhatkar RG and Chondkar SK.,21 have developed a spectrophotometric method for the
determination of Metoclopramide Hydrochloride. The drug forms a complex with a
ammonium reineckate, which is soluble in acetone showing a maximum absorbance at
526nm.
4. Kamalapurkar OS and Chudasama JJ C.,22 have developed a spectrophotometric method
for the estimation of Metoclopramide Hydrochloride in pharmaceutical dosage forms.
The method is based on coupling of diazotised derivative of Metoclopramide with
Thymol resulting in a red chromophore.
5. In BP 2003,23 a Non-aqueous titrimetric method has been described for the determination
of Metoclopramide hydrochloride in pharmaceutical formulations.
Department of Pharmaceutics, GCP, Bangalore -27.
35
Review of Literature
2.3 (c) REVIEW OF OPTIMIZATION
1. Jesusa Joyce and et. al24., have reported an experimental design, the Central
Composite which was used for the optimization of a new filler / binder (Xylitab 200) for
direct compression, with aspirin as the model drug .the design consists of four
independent variables (filler / binder, drug, disintegrant, and compression force) in
varying amounts, and with crushing strength, friability, weight variation, etc as response
variables. Multiple regression in the form of a second-order polynomial was used to
determine meaningful relationships. In this study, the amounts of compression force and
disintegrant played an important role in controlling the response variables.
2. Renoux and et. al.25, have reported the use of the factorial design for the optimization of
direct compression tablets. A two- level factorial design was used to optimize the
rheological and preformulation properties of a directly compressed tablet formulation
containing 50 % active substance of plant origin. In preformulation tests, the directly
compressible excipients, lubricants, disintegrating agents and glidants were selected. The
optimum concentration of lactose, silicon dioxide colloidal (colloidal silica, Aerosil 200)
and magnesium stearate were then determined. The experimental design revealed a
marked influence of lactose and to a lesser extent of magnesium stearate, allowing the
optimization of these components. After direct compression of an optimized formulation,
mass regularity, friability and disintegrating time was found to be 501.87 mg, 0.16 % and
20 min. respectively.
3. Lipp and Heimann 26 reported a statistical approach to optimization of drying
conditions for a transdermal delivery system (TDDS). In order to optimize the drying
conditions of the TDDS containing 22% of the partly volatile penetration enhancer
Department of Pharmaceutics, GCP, Bangalore -27.
36
Review of Literature
(propylene glycol), the key factors like drying time and drying temperature were
optimized. Using the results of the statistical analysis of a 2-factorial experiment it was
reported that the amount of residual solvent, ethyl acetate was reduced below 0.02%
while the propylene glycol content of the transdermal system was kept at the desired 22%
level.
4. Lalla and Bhat 27 reported a 23 factorial design approach for the optimization of
Non-pareil seed preparation. Two different equipments were used for the process (i.e.,
coating pan and dish pelletizer). Eight batches of pellets were prepared from calcium
phosphate dibasic (dicalcium phosphate) by varying binder concentration, drying
interval, and pan / dish speed to optimize conditions for preparing Non-pareil seeds. The
pellets were evaluated for size, size distribution, density hardness, etc. Results indicated
that binder concentration, drying, and pan speeds are the critical factors determining
pellet properties.
5. Church, Zia and Rhodes 28 developed a novel extended release Sotalol Hydrochloride
tablet formulation, which possesses a unique combination of floatation and bio adhesion
for prolonged residence in the stomach. A two- factorial, central, composite Box-Wilson
experimental design was employed to develop and optimize the tablet formulation
containing 240 mg of Sotalol Hydrochloride. The ratio of two major bioadhesive agents,
Sodium Carboxymethylcellulose, and the ratio of two directly compressible agents,
diluents, Ethyl cellulose and Crospovidone were used as formulation variables for
optimizing tablet response parameters such as dissolution, bioadhesive capacity, tablet
density and required compression force for producing 6 kg/cm2 hardness.
Department of Pharmaceutics, GCP, Bangalore -27.
37
Methodology
MATERIALS AND METHODS
The following excipients, chemicals and instruments were used for the formulation and
evaluation studies.
DRUG
Metoclopramide hydrochloride M/S Eros Pvt Ltd, Bangalore
M/S Ce-Chem laboratories, Bangalore
M/S KAPL Ltd, Bangalore
EXCIPIENTS
Dicalcium Phosphate M/S Eros Pvt Ltd, Bangalore
M/S Ce-Chem laboratories, Bangalore
Mannitol M/S Eros Pvt Ltd, Bangalore
M/S KAPL Ltd, Bangalore
Avicel PH 200 M/S Eros Pvt Ltd, Bangalore
M/S Ce-Chem laboratories, Bangalore
Aspartame Dr.Reddy’s labs, Hyderabad.
L-HPC Dr.Reddy’s labs, Hyderabad
Emcompress M/S Eros Pvt Ltd, Bangalore
Crospovidone M/S Eros Pvt Ltd, Bangalore
M/S Ce-Chem laboratories, Bangalore
Croscarmellose sodium M/S Eros Pvt Ltd, Bangalore
M/S KAPL Ltd, Bangalore
Sodium starch glycolate M/S Eros Pvt Ltd, Bangalore
Department of Pharmaceutics, GCP, B’lore-27.
38
Methodology
M/S Ce-Chem laboratories, Bangalore
Pregelatinized starch M/S KAPL Ltd, Bangalore
Magnesium stearate M/S Eros Pvt Ltd, Bangalore
M/S Ce-Chem laboratories, Bangalore
Talc M/S Eros Pvt Ltd, Bangalore
M/S Ce-Chem laboratories, Bangalore
INSTRUMENTS
Analytical balance National scientific works, Varanasi
Tablet punching machine Rimek RSB-4, minipress, Karnavati
(10 station) Engineering, Ahmedabad.
UV Visible spectrophotometer Elico UV-VIS Spectrophotometer
SL-159.
Monsanto hardness tester Praveen enterprises, Bangalore.
Friability testing apparatus Indian equipment corporation, Mumbai
Ovens Elite
Disintegration test apparatus Scientific
Dissolution test apparatus USP type 2
FT-IR spectrophotometer Shimadzu FT-IR 8400
TLC chamber Lab model
Department of Pharmaceutics, GCP, B’lore-27.
39
Methodology
PRE-FORMULATION STUDIES
METOCLOPRAMIDE HYDROCHLORIDE BP, IP, USP.23, 29, 30
PHYSICOCHEMICAL PROPERTIES
Structure:
Chemical name: 4-amino-5-chloro-N- (2-diethylaminoethyl)-2-
methoxybenzamide hydrochloride monohydrate.
Molecular Formula: C14H22Cl N3O2, HCl, H2O.
Molecular Weight: 354.3
Category: Anti-emetic.
Definition: Metoclopramide Hydrochloride contains not less
than 99.0% and not more than 101% of
C14H22Cl N3O2, HCl, H2O calculated with
reference to the anhydrous substance
Department of Pharmaceutics, GCP, Bangalore-27.
40
Methodology
Description: White or almost white crystals or crystalline
powder.
Solubility: Very soluble in water: freely soluble in ethanol
(95%); sparingly soluble in dichloromethane;
practically insoluble in ether.
Identification: a) Infra red absorption spectrometry.
b) UV spectroscopy
c) Thin Layer Chromatography.
Heavy metals: Not more than 20ppm.
Sulphated ash: Not more than 0.1%.
Storage: Store in well-closed, light resistant containers.
Assay: Tablet triturate equivalent to 250mg of
Metoclopramide Hydrochloride is dissolved in a
mixture of 50ml of ethanol and 5.0ml of 0.01M
Hydrochloric acid and titrated against 0.1M Sodium
hydroxide. The end point is determined
potentiometrically.
Each ml of 0.1M Sodium hydroxide is equivalent to
0.03363g of C14H22Cl N3O2, HCl, H2O.
Department of Pharmaceutics, GCP, Bangalore-27.
41
Methodology
Figure 1: IR spectrum of Metoclopramide Hydrochloride.
Department of Pharmaceutics, GCP, Bangalore-27.
42
Methodology
Figure 2: UV spectrum of Metoclopramide Hydrochloride in pH 1.2 buffer.
G.C.P
Mode : Spectrum Starting WL : 200.0nm Ending WL : 400.0nm Number of peaks detected: 3
0.402
Analyst: Sreenivasa Reddy N Date: 2/6/04 Sample: Metoclopramide Hydrochloride in 0.1 N HCL (pH1.2 buffer) Reference: Simulated gastric fluid (pH1.2 buffer) Concentration: 10mcg/ml Wavelength: 273.0 nm Absorbance: 0.402
Department of Pharmaceutics, GCP, Bangalore-27.
43
Methodology
STANDARD GRAPH FOR METOCLOPRAMIDE HYDROCHLORIDE
Preparation of Simulated gastric fluid (pH 1.2 Buffer)
8.5ml concentrated hydrochloric acid and 0.8gm of sodium chloride were
dissolved in 1000ml of distilled water.
Instrument
Elico UV-Visible Spectrophotometer SL159.
Principle
Metoclopramide Hydrochloride showed maximum absorbance at 273 nm in 0.1N
Hydrochloric acid and obeyed Beer’s law at the concentration range between 2-25
mcg/ml.
Procedure
Stock solution
Weighed quantity of Metoclopramide Hydrochloride (100mg) was dissolved in
pH 1.2 buffer and the volume made up to 100ml with the same.
S.S I ⇒ 1000 mcg/ml.
10ml of Stock solution I was further diluted with 100ml of pH 1.2 buffer to get a working
standard S.S I ⇒ 100mcg/ml
Aliquots of 1.0, 3.0, 5.0, 7.0, 9.0,and 11.0ml of stock solution was pipetted into
50ml volumetric flask and the volume was made upto 50ml with pH 1.2 buffer. The
absorbance was measured at 273 nm against reagent blank (pH 1.2 buffer).
Department of Pharmaceutics, GCP, Bangalore-27.
44
Methodology
Table 1: Calibration curve of Metoclopramide Hydrochloride in pH 1.2 buffer
Absorbance at 273nm Vol. of
SSII (ml)
Vol. made
Upto (ml)
Conc.
(mcg/ml) Trial I Trial II Trial III Avg. SEM
1.0 50 2 0.089 0.088 0.087 0.088 0.0006
3.0 50 6 0.241 0.241 0.239 0.240 0.0007
5.0 50 10 0.391 0.39 0.395 0.392 0.0015
7.0 50 14 0.549 0.547 0.549 0.548 0.0007
9.0 50 18 0.702 0.700 0.700 0.701 0.0007
11.0 50 22 0.856 0.855 0.857 0.856 0.0006
Figure 3:
Standard Curve of Metoclopramide Hydrochloride (pH 1.2 Buffer).
y = 0.0387x + 0.0063R2 = 0.9999
00.1
0.20.3
0.40.5
0.60.7
0.80.9
0 2 4 6 8 10 12 14 16 18 20 22 24 26
Conc.(mcg/ml)
Abs
orba
nce
Department of Pharmaceutics, GCP, Bangalore-27.
45
Methodology
COMPATIBILITY STUDIES
The proper design and formulation of a dosage form requires consideration of the
physical, chemical and biological characteristics of all drug substances and excipients to
be used in the fabricating the product. The drug and excipients must be compatible with
one another to produce a product that is stable, efficacious, attractive, and easy to
administer and safe.
If the excipients are new and not been used in formulations containing the active
substance, the compatibility studies are of paramount importance.
Figure 4: Schematic representation of Drug- Excipient compatibility studies
Drug
M eTLC
Excipients
No Interaction
Method
Drug and excipients
samples were analysed
and seven weeks as pe
Department of Pharm
1:1 ixtur
Interacti
in 1:1 ratio were mixed and stored in glass vi
for compatibility by Thin Layer Chromatograph
r the method described below.
aceutics, GCP, Bangalore-27.
Recommendexcipients
on
Alternative Excipients?als at 500C. The
y after one, three
46
Methodology
Stationary phase: Thin plate of Silica gel G having thickness of 0.25cm.
The plates were activated at 1050C for 30min prior to
use.
Mobile phase: Benzene: Methanol: Ammonia (75:25:0.25)
Separation technique: Ascending
Reference solution: 5mg of Metoclopramide hydrochloride was shaken with
5ml of methanol, decanted and used for spotting
Test solution: Drug-Excipient mixture equivalent to 5mg of
Metoclopramide HCl was shaken with 5ml of methanol,
decanted and used for spotting
Procedure: - 10µl of reference and test solutions were applied as spots on the dry
activated plate. The solvent system was allowed to run upto a desired height; the plates
were removed and allowed to dry. The dry plates were then exposed to iodine vapors in a
chamber to observe the spots. The plates ere then removed and the Rf values calculated.
Rf = Distance of the solute from the starting point Distance of the solvent from the starting point
Department of Pharmaceutics, GCP, Bangalore-27.
47
Methodology
Table 2: Drug- Excipient compatibility – Rf values.
Spot No. Sample Rf values
A Drug 0.44
B Drug + Avicel PH 200 0.44
C Drug + Dibasic Calcium Phosphate 0.44
D Drug + Mannitol DC 0.44
E Drug + L-HPC 0.44
F Drug + Crospovidone 0.44
G Drug + Croscarmellose Sodium 0.44
H Drug + Sodium Starch Glycolate 0.44
I Drug + Pregelatinized starch 0.44
J Drug + Aspartame 0.44
K Drug + Magnesium stearate 0.44
L Drug + Talc 0.44
Department of Pharmaceutics, GCP, Bangalore-27.
48
Methodology
Figure 5: TLC profile of compatibility studies after 7 weeks.
A G H I J K L
A Drug
B Drug + Avicel PH 200
C Drug + Dibasic Calcium Phosphate
D Drug + Mannitol DC
E Drug + L-HPC
F Drug + Crospovidone
G Drug + Croscarmellose Sodium
H Drug + Sodium Starch Glycolate
I Drug + Pregelatinized starch
J Drug + Aspartame
K Drug + Magnesium stearate
L Drug + Talc
Department of Pharmaceutics, GCP, Bangalore-27.
49
Methodology
FORMULATION OF TABLETS
DIRECT COMPRESSION METHOD
The tablets were formulated employing direct compression method using 8mm
flat-faced punches. It is the process by which tablets are compressed directly from
mixtures of the drug and excipients without preliminary treatment such as granulation.
The steps involved are as follows:
Drug
Filler
Disintegrant
Sweetening agent Blending Compression
Lubricant
Glidant
Experimental Design
Factorial design is an experimental design technique, by which the factor involved and
their relative importance can be assessed. In the present study, the runs or formulations,
which are designed based on 32 full factorial design containing 2 factors evaluated at
three levels and the experimental trials were, performed at all possible combinations.
Department of Pharmaceutics, GCP, B’lore-27.
50
Methodology
The two independent formulation variables evaluated include:
Factor A: Amount of SSG in milligram (X1) (5, 12.5, 20)
Factor B: Amount of CPVP in milligram (X2). (5, 8.75, 12.5)
32 full factorial design was considered, according to the model totally 11
experiments were conducted with three replicates of center point.
Table 3: Actual and coded values of the factors
Model Actual values Coded values
Factor Low level Mid level High level low mid High
Factor -A 5 12.5 20 -1 0 +1
Factor-B 5 8.75 12.5 -1 0 +1
The coded levels are calculated using the following formula:
X - The average of the two levels
Level = Half the difference of the level
Department of Pharmaceutics, GCP, B’lore-27.
51
Methodology
Table 4: Runs Designed In Actual and Coded Values
Coded values Actual values Runs Type
Factor A Factor B Factor A Factor B
1 CentEdge 0 1 12.50 12.50
2 Center 0 0 12.50 8.75
3 Fact -1 1 5.00 12.50
4 CentEdge -1 0 5.00 8.75
5 Fact -1 -1 5.00 5.00
6 CentEdge 1 0 20.00 8.75
7 Fact 1 1 20.00 12.50
8 Fact 1 -1 20.00 5.00
9 Center 0 0 12.50 8.75
10 Center 0 0 12.50 8.75
11 CentEdge 0 -1 12.50 5.00
Department of Pharmaceutics, GCP, B’lore-27.
52
Table 5: Dibasic Calcium Phosphate based tablet formulations.
*INGREDIENTS D1 D 2 D 3 D 4 D 5 D 6 D 7 D 8 D 9 D10 D11 D12
Metoclopramide HCl 10 10 10 10 10 10 10 10 10 10 10 10
Calcium phosphate dibasic 190.5 188.0 185.5 190.5 188.0 185.5 190.5 188.0 185.5 185.5 183.0 180.5
Cross Povidone 5 7.5 10 - - - - - - - - -
Croscarmellose Sodium - - - 5 7.5 10 - - - - - -
L-HPC - - - - - - 5 7.5 10 - - -
Sodium Starch Glycolate - - - - - - - - - 10 12.5 15
Pregelatinized Starch 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5
Aspartame 5 5 5 5 5 5 5 5 5 5 5 5
Magnesium Stearate 4 4 4 4 4 4 4 4 4 4 4 4
Talc 4 4 4 4 4 4 4 4 4 4 4 4
TOTAL 250 250 250 250 250 250 250 250 250 250 250 250
*All the quantities expressed are in mg / tablet
.
53
Table 6: Mannitol based tablet formulations.
*INGREDIENTS M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12
Metoclopramide HCl 10 10 10 10 10 10 10 10 10 10 10 10
Mannitol 190.5 188 185.5 190.5 188 185.5 190.5 188 185.5 185.5 183. 180.5
Cross Povidone 5 7.5 10 - - - - - - - - -
Croscarmellose Sodium - - - 5 7.5 10 - - - - - -
L-HPC - - - - - - 5 7.5 10 - - -
Sodium Starch Glycolate - - - - - - - - - 10 12.5 15
Pregelatinized Starch 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5
Aspartame 5 5 5 5 5 5 5 5 5 5 5 5
Magnesium Stearate 4 4 4 4 4 4 4 4 4 4 4 4
Talc 4 4 4 4 4 4 4 4 4 4 4 4
TOTAL 250 250 250 250 250 250 250 250 250 250 250 250
*All the quantities expressed are in mg / tablet.
54
Table 7: Avicel PH200 based tablet formulations.
*INGREDIENTS A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12
Metoclopramide HCl 10 10 10 10 10 10 10 10 10 10 10 10
Avicel PH200 190.5 188 185.5 190.5 188 185.5 190.5 188 185.5 185.5 183. 180.5
Cross Povidone 5 7.5 10 - - - - - - - - -
Croscarmellose Sodium - - - 5 7.5 10 - - - - - -
L-HPC - - - - - - 5 7.5 10 - - -
Sodium Starch Glycolate - - - - - - - - - 10 12.5 15
Pregelatinized Starch 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5
Aspartame 5 5 5 5 5 5 5 5 5 5 5 5
Magnesium Stearate 4 4 4 4 4 4 4 4 4 4 4 4
Talc 4 4 4 4 4 4 4 4 4 4 4 4
TOTAL 250 250 250 250 250 250 250 250 250 250 250 250
*All the quantities expressed are in mg / table.
55
Table 8: Runs as per DOE using Avicel PH 200 as diluent.
*INGREDIENTS R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11
Metoclopramide HCl 10 10 10 10 10 10 10 10 10 10 10
Avicel PH200 178 185.5 174.25 178 163 166.75 174.25 170.5 174.25 181.75 170.5
Cross Povidone 5 5 8.75 12.5 12.5 8.75 8.75 12.5 8.75 8.75 5
Sodium Starch Glycolate 12.5 5 12.5 5 20 20 12.5 12.5 12.5 5 20
Pregelatinized Starch 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5
Aspartame 5 5 5 5 5 5 5 5 5 5 5
Magnesium Stearate 4 4 4 4 4 4 4 4 4 4 4
Talc 4 4 4 4 4 4 4 4 4 4 4
TOTAL 250 250 250 250 250 250 250 250 250 250 250
*All the quantities expressed are in mg / tablet.
56
Methodology
EVALUATION PARAMETERS
Precompression Parameters
1. Bulk Density (Db):
It is the ratio of total mass of powder to the bulk volume of powder. It was
measured by pouring the weighed powder into a measuring cylinder and the volume
was noted. It is expressed in gm/ml and is given by
Where, M is the
mass of powder 0
b VMD =
V0 is the Bulk volume of the powder.
2. Tapped Density (Dt):
It is the ratio of total mass of powder to the tapped volume of powder. The tapped
volume was measured by tapping the powder to constant volume. It is expressed in
gm/ml and is given by
Where, M is the mass of powder
tt V
MD =
Vt is the tapped volume of the powder.
Department of Pharmaceutics, GCP, B’lore-27.
57
Methodology
3. Angle of Repose:
The frictional forces in a loose powder can be measured by the angle of repose, θ.
This is the maximum angle possible between the surface of a pile of powder and the
horizontal plane.
tan θ = h / r
θ = tan-1 (h / r)
Where, θ is the angle of repose
h is the height in cms
r is the radius.
The powder mixture was allowed to flow through the funnel fixed to a stand at
definite height. The angle of repose was then calculated by measuring the height and
radius of the heap of powder formed.
4. Carr’s Index (I):
It indicates the ease with which a material can be induced to flow. It is expressed
in percentage and is given by
100
DDDI
t
bt ×−
=
Where, Dt is the tapped density of the powder.
Db is the bulk density of the powder.
Department of Pharmaceutics, GCP, B’lore-27.
58
Methodology
Table 9: Carr’s index values
Carr’s index (%) Type of flow
5 – 15 Excellent
12 – 18 Good
18 – 23 Fair to passable
23 – 35 Poor
35 – 38 Very poor
> 40 Extremely poor
Post compression Parameters
5. Hardness:
The hardness of the tablet was determined using a Monsanto hardness tester. It is
expressed in Kg / cm2.
6. Friability (F):
The friability of the tablet was determined using Roche Friabilator. It is expressed
in percentage (%). 10 tablets were initially weighed (Winitial) and transferred into the
friabilator. The friabilator was operated at 25 rpm for four mins. The tablets were
weighed again (Wfinal). The percentage friability was then calculated by:
Department of Pharmaceutics, GCP, B’lore-27.
59
Methodology
100W
WWFinitial
finalinitial ×−
=
7. Weight Variation:
Ten tablets were selected randomly from the lot and weighed individually to
check for weight variation. IP limit for weight variation in case of tablets weighing
upto 250mg is ± 7.5%
8. Thickness:
The thickness of the tablets was measured by screw gauge. It is expressed in mm.
9. Disintegration Time:
The Invitro disintegration time was determined using disintegration test apparatus.
A tablet was placed in each of the six tubes of the apparatus and one disc was added
to each tube. The time in seconds taken for complete disintegration of the tablet with
no palpable mass remaining in the apparatus was measured in seconds.
10. Disintegration time in oral cavity:
The disintegration time in the oral cavity of human volunteers was measured by
placing the tablet on the tongue until no lumps remain. It is expressed in seconds.
Department of Pharmaceutics, GCP, B’lore-27.
60
Methodology
11. Wetting Time:
A piece of tissue paper folded twice was placed in a small petri plate (internal
diameter = 6.5 cm) containing 10ml of water. A tablet was placed on the paper, and
the time for complete wetting of the tablet was measured in seconds. The method was
slightly modified by maintaining water at 37o C (Photograph in next page)
12. Assay:
10 tablets were weighed and triturated. The tablet triturate equivalent to 10 mg of
the drug was weighed accurately, dissolved in pH 1.2 buffer and diluted to 100 ml
with the same. Further dilutions were done suitably to get a concentration of 10 mcg /
ml with simulated gastric fluid pH 1.2. Absorbance was read at 273 nm against the
reagent blank, and the concentrations of Metoclopramide hydrochloride in mcg / ml
was determined by using the regression equation.
Y = 0.0387x + 0.0063
Drug content in mg / tablet = conc. mcg / ml * dilution factor
% Drug content = drug content in mg * 100 / label claim.
Department of Pharmaceutics, GCP, B’lore-27.
61
Methodology
13. Invitro dissolution studies:
The Invitro dissolution study was carried out in USP dissolution test apparatus type 2
(paddle)
Dissolution Medium : 900ml of simulated gastric fluid
Temperature : 37 ± 0.5 o C
RPM : 50
Tablets taken : 2 tablets were weighed & taken for study
Volume withdrawn & replaced : 5 ml every five minutes.
λ max : 273 nm
Beer’s range : 2 –25 mcg /ml.
14. Optimization
The runs or formulations, which are designed based on 32 full factorial designs, are
evaluated for the response variables. The response values are subjected to multiple
regression analysis to find out the relationship between the factors used and the response
values obtained. The response values subjected for this analysis are;
1. Wetting time (WT) in seconds.
2. Disintegration time (DT) in seconds.
Department of Pharmaceutics, GCP, B’lore-27.
62
Methodology
The Wetting time and Disintegration time were chosen for analysis of the following
relationship:
1. To study the effect of amount of SSG
2. To study the effect of amount of CPVP.
3. To study the combined effect of SSG and CPVP.
STATISTICAL ANALYSIS
The effect of formulation variables on the response variables were statically evaluated by
applying one-way ANOVA at 0.05 level using a commercially available software
package Design of Experiments® 6.05 (Stat Ease, USA). The design was evaluated by
quadratic model, which bears the form of equation (1).
Y= b0 + b1 X1+ b2 X2 + b3 X1 X2 + b4 X12 + b5 X2 2 eq-1
Where y is the response variable, b0 the constant and b1, b2, b3…b5 is the regression
coefficient. X1 and X2 stand for the main effect; X1X2 are the interaction terms, show
how response changes when two factors are simultaneously changed. X12, X2
2 are
quadratic terms of the independent variables to evaluate the nonlinearity. The results of
this analysis are presented in the table.
Using the regression coefficient of the factors, the polynomial equation for the response
is constructed. Only significantly, contributing factors are considered for the equation
generation.
Department of Pharmaceutics, GCP, B’lore-27.
63
Methodology
Desirability Details
The method makes use of an objective function, D (X), called the desirability function. It
reflects the desirable ranges for each response (di). The desirable ranges are from zero to
one (least to most desirable respectively). The simultaneous objective function is a
geometric mean of all transformed responses:
If any of the responses or factors falls outside their desirability range, the overall function
becomes zero. For simultaneous optimization each response must have a low and high
value assigned to each goal.
Maximum:
di = 0 if response < low value
0 < di < 1 as response varies from low to high
di = 1 if response > high value
Minimum:
di = 1 if response < low value
1 <di < 0 as response varies from low to high
di = 0 if response > high value
Target:
di = 0 if response < low value
0 < di < 1 as response varies from low to target
1 < di < 0 as response varies from target to high
di = 0 if response > high value
Range:
di = 0 if response < low value
Department of Pharmaceutics, GCP, B’lore-27.
64
Methodology
di = 1 as response varies from low to high
di = 0 if response > high value
STABILITY STUDIES
INTRODUCTION
In any rational design and evaluation of dosage forms for drugs, the stability of
the active component must be a major criterion in determining their acceptance or
rejection.
Stability of a drug can be defined as the ability of a particular formulation, in a
specific container, to remain within its physical, chemical, therapeutic and toxicological
specifications.
Or
Stability of a drug can be defined as the time from the date of manufacture and the
packaging of the formulation, until its chemical or biological activity is not less than a
predetermined level of labeled potency and its physical characteristics have not changed
appreciably or deleteriously.
Department of Pharmaceutics, GCP, B’lore-27.
65
Methodology
4.6.2 OBJECTIVE OF THE STUDY
The purpose of stability testing is to provide evidence on how the quality of a
drug substance or drug product varies with time under the influence of a variety of
environmental factors such as temperature, humidity and light, enabling recommended
storage conditions, re-test periods and shelf-lives.
Generally, the observation of the rate at which the product degrades under normal
room temperature requires a long time. To avoid this undesirable delay, the principles of
accelerated stability studies are adopted.
The International Conference on Harmonization (ICH) Guidelines titled
“stability testing of New Drug substance and products” (QIA) describes the stability test
requirements for drug registration applications in the European Union, Japan and the
United States of America.
ICH specifies the length of study and storage conditions.
Long-Term Testing: 250 C ± 20 C / 60% RH ± 5% for 12 Months
Accelerated Testing: 400 C ± 20 C / 75% RH ± 5% for 6 Months
Stability studies were carried out at 250 C / 60% RH and 400 C / 75% RH for the
optimized formulation for 2 months.
Method
The selected formulations were packed in amber-colored bottles, which were
tightly plugged with cotton and capped. They were then stored at 250 C / 60% RH and
400 C / 75% RH for 2 months and evaluated for their physical appearance, drug content
and drug excipient compatibility at specified intervals of time.
Department of Pharmaceutics, GCP, B’lore-27.
66
RESULTS
Table 10: Pre-compression parameters of Dibasic Calcium Phosphate formulations
PARAMETERS D1 D 2 D 3 D 4 D 5 D 6 D 7 D 8 D 9 D10 D11 D12
Bulk Density (g/cc) 0.79 0.83 0.84 0.88 0.72 0.8 0.85 0.79 0.76 0.73 0.83 0.88Tapped Density (g /cc) 0.65 0.68 0.69 0.71 0.61 0.67 0.69 0.62 0.59 0.58 0.69 0.71
Angle of Repose (θ) 32.4 35.3 33.2 37.3 36.5 33.5 36.3 32.5 33.0 34.0 33.4 33.8Carr’s Index (%) 17.722 18.07 17.86 19.32 15.28 16.25 18.82 21.52 22.37 20.55 16.87 19.32
Table 11: Post compression parameters of Dibasic Calcium Phosphate formulations.
PARAMETERS D1 D 2 D 3 D 4 D 5 D 6 D 7 D 8 D 9 D10 D11 D12
Hardness (kg / cm2) 3.5 4.0 3.5 4.0 3.5 4.0 4.0 3.5 4.0 3.8 3.5 3.8Friability (%) 0.21 0.23 0.19 0.19 0.18 0.21 0.20 0.18 0.16 0.19 0.23 0.25
Thickness (mm) 3.07 2.98 2.79 2.81 2.79 2.90 3.01 2.96 9.90 2.88 2.93 2.96Drug content (%) 95.65 96.68 98.47 98.98 99.74 100.26 97.95 96.68 97.44 96.48 98.98 97.44Weight Variation 239 mg to 253 mg (IP limit: 231.25 mg to 268.75 mg)
67
Table No. 12 Comparison between Disintegration Time, Disintegration time in Oral cavity, and Wetting time.
PARAMETERS D1 D 2 D 3 D 4 D 5 D 6 D 7 D 8 D 9 D10 D11 D12
Average* 35.67 32.00 30.67 55.00 49.00 46.00 59.67 58.00 54.87 45.00 43.00 37.00DT in oral
cavity in (sec)
SEM n = 3 0.333 0.577 0.667 0.577 0.577 1.155 0.882 0.577 0.333 0.577 0.577 0.577
Average* 35.67 34.00 25.00 48.00 43.00 41.00 59.00 51.00 47.67 46.00 43.33 40.67Wetting time (sec) SEM
n = 3 0.333 0.577 0.577 0.577 0.577 0.577 0.577 0.577 0.333 1.528 0.882 0.333
Average* 39.67 35.33 29.00 65.00 52.00 54.0 77.00 45.00 37.00 50.00 45.67 40.67DT in (sec) SEM
n = 3 0.882 0.667 0.577 0.577 0.577 0.577 0.577 0.577 1.528 0.577 0.333 0.333
*Average of 3 trials
68
0
20
40
60
80
100
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12
Dis
inte
grat
ion
Tim
e (s
ec)
In Vitro DT Wetting Time DT in Oral Cavity
Figure 6: DISINTEGRATION PROFILE OF DCP FORMULATIONS
69
Results
Department of Pharmaceutics, GCP, B’lore-27 .66
Results
In Vitro Release rate profile of Dibasic Calcium Phosphate formulations in simulated gastric fluid (pH 1.2) after 5 and 20 mins
Table No. 13
Formulations Absorbance Conc. (mcg /ml)
Conc. (mg / 5ml)
Conc. (mg/900ml) CLA CDR
%CDR after 5
mins D1 0.370 9.525 0.048 8.573 0 8.573 89.581 D2 0.361 9.284 0.046 8.356 0 8.356 86.409 D3 0.348 8.936 0.045 8.042 0 8.042 81.646 D4 0.373 9.606 0.048 8.645 0 8.645 87.326 D5 0.370 9.525 0.048 8.573 0 8.573 85.987 D6 0.368 9.472 0.047 8.525 0 8.525 84.992 D7 0.370 9.525 0.048 8.573 0 8.573 87.568 D8 0.370 9.525 0.048 8.573 0 8.573 88.655 D9 0.367 9.445 0.047 8.501 0 8.501 87.274 D10 0.370 9.525 0.048 8.573 0 8.573 88.931 D11 0.373 9.606 0.048 8.645 0 8.645 87.326 D12 0.399 10.303 0.052 9.273 0.0946 9.367 94.619
Table No. 14
Formulations Absorbance Conc. (mcg /ml)
Conc. (mg / 5ml)
Conc. (mg/900ml) CLA CDR
%CDR after 20
mins D1 0.399 10.303 0.052 9.273 0.0946 9.367 97.881 D2 0.402 10.383 0.052 9.345 0.0966 9.442 97.638 D3 0.412 10.651 0.053 9.586 0.0927 9.679 98.264 D4 0.409 10.571 0.053 9.514 0.0975 9.611 97.086 D5 0.399 10.303 0.052 9.273 0.0946 9.367 93.954 D6 0.401 10.357 0.052 9.321 0.0943 9.415 93.871 D7 0.399 10.303 0.052 9.273 0.0946 9.367 95.682 D8 0.393 10.142 0.051 9.128 0.0946 9.222 95.372 D9 0.399 10.303 0.052 9.273 0.0946 9.367 96.173 D10 0.393 10.142 0.051 9.128 0.0942 9.222 94.682 D11 0.396 10.223 0.051 9.200 0.0950 9.295 93.891 D12 0.396 10.223 0.051 9.200 0.0946 9.295 95.430
Department of Pharmaceutics, GCP, B’lore-27. 70
Results
Figure 7: Dissolution Profile of Dicalcium Phosphate Formulations in Simulated Gastric Fluid (pH 1.2) after 5 and 20 minutes.
0
20
40
60
80
100
120
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12
%C
DR
After 5mins After 20 mins
Department of Pharmaceutics, GCP, B’lore-27. 71
Table 15: Pre-compression parameters of Mannitol formulations
72
PARAMETERS M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12
Bulk Density (g/cc) 0.79 0.83 0.84 0.88 0.72 0.8 0.85 0.79 0.76 0.73 0.83 0.88Tapped Density (g /cc) 0.65 0.68 0.69 0.71 0.61 0.67 0.69 0.62 0.59 0.58 0.69 0.71
Angle of Repose (θ) 32.4 35.3 33.2 37.3 36.5 33.5 36.3 32.5 33.0 34.0 33.4 33.8Carr’s Index (%) 17.722 18.07 17.86 19.32 15.28 16.25 18.82 21.52 22.37 20.55 16.87 19.32
Table 16: Post compression parameters of Mannitol formulations
PARAMETERS M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12
Hardness (Kg / cm2) 2.8 3.0 2.8 3.0 2.8 2.8 3.2 3.0 3.0 2.8 3.0 3.2Friability (%) 0.59 0.40 0.64 0.58 0.52 0.63 0.56 0.58 0.60 0.65 0.57 0.58
Thickness (mm) 4.14 4.01 4.02 4.01 4.05 4.08 4.11 4.10 4.15 4.02 4.15 4.10Drug content (mg) 97.95 100.51 98.47 98.78 97.19 96.68 95.65 98.88 96.68 94.38 95.91 96.16 Weight Variation 239 mg to 253 mg (IP limit: 231.25 mg to 268.75 mg)
Table No. 17 Comparison between Disintegration Time, Disintegration time in Oral cavity, and Wetting time.
73
PARAMETERS M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12
Average* 65.67 44.33 25.33 70.67 44.00 40.00 69.00 63.00 52.00 53.67 50.67 42.67DT in oral
cavity in (sec)
SEM n = 3 0.333 0.333 0.333 0.333 0.577 0.577 0.577 0.577 0.577 0.333 0.333 0.333
Average* 24.00 21.33 20.00 29.67 28.00 28.67 32.00 30.00 25.33 29.33 28.67 25.67Wetting time (sec) SEM
n = 3 0.577 0.667 0.000 0.333 0.000 0.333 0.000 0.333 0.667 0.667 0.333 0.333
Average* 24.67 22.33 19.33 26.33 24.67 24.00 28.33 25.67 2.67 30.00 26.33 22.67DT in (sec) SEM
n = 3 0.882 1.764 2.186 0.882 0.667 0.000 0.667 0.333 0.667 1.155 0.882 0.333
* Average of 3 trials
0
20
40
60
80
100
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12
Dis
inte
grat
ion
Tim
e (s
ec)
In Vitro DT Wetting Time DT in Oral Cavity
Figure 8: DISINTEGRATION PROFILE OF MANNITOL FORMULATIONS
74
Results
Department of Pharmaceutics, GCP, B’lore-27.
Results
In Vitro Release rate profile of Mannitol formulations in simulated gastric fluid (pH 1.2) after 5 and 20 mins
Table No. 18
Formulations Absorbance Conc. (mcg /ml)
Conc. (mg / 5ml)
Conc. (mg/900ml) CLA CDR
%CDR after 5
mins M1 0.38 9.794 0.049 8.814 0 8.814 90.033 M2 0.361 9.284 0.046 8.356 0 8.356 83.142 M3 0.362 9.311 0.047 8.380 0 8.380 84.903 M4 0.376 9.686 0.048 8.718 0 8.718 88.325 M5 0.374 9.633 0.048 8.669 0 8.669 89.284 M6 0.371 9.552 0.048 8.597 0 8.597 88.996 M7 0.385 9.928 0.050 8.935 0 8.935 90.709 M8 0.361 9.284 0.046 8.356 0 8.356 83.558 M9 0.365 9.391 0.047 8.452 0 8.452 84.948 M10 0.378 9.740 0.049 8.766 0 8.766 88.545 M11 0.374 9.633 0.048 8.669 0 8.669 88.015 M12 0.369 9.499 0.047 8.549 0 8.549 87.680
Table No. 19
Formulations Absorbance Conc. (mcg /ml)
Conc. (mg / 5ml)
Conc. (mg/900ml) CLA CDR
%CDR after 20
mins M1 0.401 10.357 0.052 9.321 0.1001 9.421 96.231 M2 0.418 10.812 0.054 9.731 0.0975 9.829 97.797 M3 0.408 10.544 0.053 9.490 0.0967 9.587 97.128 M4 0.414 10.705 0.054 9.635 0.0998 9.734 98.626 M5 0.409 10.571 0.053 9.514 0.0979 9.612 98.989 M6 0.399 10.303 0.052 9.273 0.0973 9.370 96.997 M7 0.407 10.517 0.053 9.466 0.1008 9.566 97.121 M8 0.42 10.866 0.054 9.779 0.0975 9.877 98.769 M9 0.414 10.705 0.054 9.635 0.0971 9.732 97.806 M10 0.415 10.732 0.054 9.659 0.1001 9.759 98.574 M11 0.409 10.571 0.053 9.514 0.0979 9.612 97.583 M12 0.407 10.517 0.053 9.466 0.0970 9.563 98.079
Department of Pharmaceutics, GCP, B’lore-27. 75
Results
Figure 9: Dissolution Profile of Mannitol Formulations in Simulated Gastric Fluid (pH 1.2) after 5 and 20 minutes.
75
80
85
90
95
100
105
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12
%C
DR
After 5 mins After 20 mins
Department of Pharmaceutics, GCP, B’lore-27. 76
Table 20: Pre-compression parameters of Avicel formulations
PARAMETERS A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12
Bulk Density (g/cc) 0.79 0.83 0.84 0.88 0.72 0.8 0.85 0.79 0.76 0.73 0.83 0.88Tapped Density (g /cc) 0.65 0.68 0.69 0.71 0.61 0.67 0.69 0.62 0.59 0.58 0.69 0.71
Angle of Repose (θ) 32.4 35.3 33.2 37.3 36.5 33.5 36.3 32.5 33.0 34.0 33.4 33.8Carr’s Index (%) 17.722 18.07 17.86 19.32 15.28 16.25 18.82 21.52 22.37 20.55 16.87 19.32
Table 21: Post compression parameters of Avicel formulations.
PARAMETERS A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12
Hardness (Kg / cm2) 3.0 3.2 3.2 3.2 2.8 3.2 3.1 3.0 2.8 2.8 3.0 3.2Friability (%) 0.49 0.51 0.59 0.39 0.48 0.41 0.51 0.48 0.49 0.52 0.48 0.50
Thickness (mm) 2.30 2.15 2.18 2.20 2.19 2.21 2.31 2.22 2.24 2.23 2.32 2.40Drug content (%) 96.93 95.91 94.37 97.44 97.95 95.91 97.44 96.93 96.16 99.49 95.91 96.93Weight Variation 239 mg to 253 mg (IP limit: 231.25 mg to 268.75 mg)
77
Table 22: Comparison between Disintegration Time, Disintegration time in Oral cavity, and Wetting time.
PARAMETERS A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12
Average* 24.67 24.00 24.00 27.00 30.67 27.00 29.00 27.00 27.67 23.33 20.67 19.33DT in oral
cavity in (sec)
SEM n = 3 0.333 0.577 1.155 0.577 0.667 0.577 0.577 0.577 0.333 0.667 0.333 0.333
Average* 27.67 24.67 21.33 30.33 25.33 25.67 29.33 26.67 22.67 27.67 24.67 23.33Wetting time (sec) SEM
n = 3 0.333 0.333 0.667 0.667 0.333 0.333 0.667 0.333 0.33 0.333 0.333 0.667
Average* 27.00 25.33 20.00 30.33 31.33 25.33 28.67 27.00 27.67 23.33 20.33 19.33DT in (sec) SEM
n = 3 0.577 0.333 0.577 0.333 0.333 0.667 0.333 0.577 0.333 0.667 0.333 0.667
78
0
10
20
30
40
50
60
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12
Dis
inte
grat
ion
Tim
e(se
c)
DT WT DTO
Figure 10: DISINTEGRATION PROFILE OF AVICEL PH 200 FORMULATIONS
79
Results
Department of Pharmaceutics, GCP, B’lore-27.
Results
In Vitro Release rate profile of Avicel PH 200 formulations in simulated gastric fluid (pH 1.2) after 5 and 20 mins
Table 23:
Formulations Absorbance Conc. (mcg /ml)
Conc. (mg / 5ml)
Conc. (mg/900ml) CLA CDR
%CDR after 5
mins A1 0.385 9.928 0.050 8.935 0 8.935 92.21 A2 0.368 9.472 0.047 8.525 0 8.525 88.89 A3 0.370 9.525 0.048 8.573 0 8.573 90.81 A4 0.365 9.391 0.047 8.452 0 8.452 86.78 A5 0.361 9.284 0.046 8.356 0 8.356 85.35 A6 0.355 9.123 0.046 8.211 0 8.211 85.62 A7 0.369 9.499 0.047 8.549 0 8.549 87.77 A8 0.365 9.391 0.047 8.452 0 8.452 87.23 A9 0.364 9.365 0.047 8.428 0 8.428 87.61 A10 0.374 9.633 0.048 8.669 0 8.669 87.13 A11 0.366 9.418 0.047 8.476 0 8.476 88.39 A12 0.355 9.123 0.046 8.211 0 8.211 84.74
Table 24:
Formulations Absorbance Conc. (mcg /ml)
Conc. (mg / 5ml)
Conc. (mg/900ml) CLA CDR
%CDR after 20
mins A1 0.410 10.598 0.053 9.538 0.1001 9.638 99.46 A2 0.398 10.276 0.051 9.249 0.0970 9.346 97.45 A3 0.395 10.196 0.051 9.176 0.0967 9.273 98.23 A4 0.405 10.464 0.052 9.417 0.0974 9.515 97.69 A5 0.411 10.625 0.053 9.562 0.0974 9.660 98.67 A6 0.402 10.383 0.052 9.345 0.0958 9.441 98.44 A7 0.408 10.544 0.053 9.490 0.0970 9.587 98.43 A8 0.405 10.464 0.052 9.417 0.0965 9.514 98.18 A9 0.402 10.383 0.052 9.345 0.0959 9.441 98.14 A10 0.415 10.732 0.054 9.659 0.0986 9.757 98.06 A11 0.411 10.625 0.053 9.562 0.0981 9.660 100.73 A12 0.408 10.544 0.053 9.490 0.0958 9.586 98.92
Department of Pharmaceutics, GCP, B’lore-27. 80
Results
Figure 11: Dissolution Profile of Avicel PH 200 Formulations in Simulated Gastric Fluid (pH 1.2) After 5 and 20mins
75
80
85
90
95
100
105
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12
%C
DR
After 5 mins After 20 mins
Department of Pharmaceutics, GCP, B’lore-27. 81
Results
OPTIMIZATION
The runs or formulations, which are designed based on central composite design,
are evaluated for the response. The response values are subjected to multiple regression
analysis to find out the relationship between the factors used and the response values
obtained. The response values subjected for this analysis are;
1. Wetting time in seconds.
2. Disintegration time in seconds.
The duration of Wetting time and Disintegration time were chosen for the analysis
of the following relationship:
1. To study the effect of amount of SSG
2. To study the effect of amount of CPVP.
3. To study the combined effect of SSG and CPVP
The multiple regression analysis was done using design expert 6.05 (STAT-
EASE) software, which is specially meant for this optimization process. The results of
this analysis are presented in the table 31.
Using the regression coefficient of the factors, the polynomial equation for the response
is constructed. Only significantly, contributing factors are considered for the equation
generation.
Department of Pharmaceutics, GCP, B’lore-27.
82
Results
Table 25 : Design and Summary Response Data
Run TYPE SSG CPVP WT DT
1 CentEdge 12.50 12.50 45 20
2 Center 12.50 8.75 40 15
3 Fact 5.00 12.50 17 19
4 CentEdge 5.00 8.75 31 19
5 Fact 5.00 5.00 28 18
6 CentEdge 20.00 8.75 37 14
7 Fact 20.00 12.50 50 28
8 Fact 20.00 5.00 38 23
9 Center 12.50 8.75 37 14
10 Center 12.50 8.75 37 13
11 CentEdge 12.50 5.00 20 19
SSG: Sodium Starch Glycolate CPVP: Crospovidone
Department of Pharmaceutics, GCP, B’lore-27.
83
Results
Response: WT Table 26: ANOVA for Response Surface Cubic Model
Source Sum of Squares DF Mean Square F Value Prob >F Model 962.48 7 137.50 20.37 0.0156
A 18.00 1 18.00 2.67 0.2010 B 312.50 1 312.50 46.30 0.0065 A2 5.70 1 5.70 0.84 0.4259 B2 22.80 1 22.80 3.38 0.1634 AB 132.25 1 132.25 19.59 0.0214 A2B 200.08 1 200.08 29.64 0.0122 AB2 80.08 1 80.08 11.86 0.0411
Residual 20.25 3 6.75 - - Lack of fit 14.25 1 14.25 4.75 0.1611
Pure 6.00 2 3.00 - - Cor Total 982.73 10 - - -
Table 27: Estimated Regression Coefficient
Factor Coefficient Estimate DF Intercept 37.00 1 A- SSG 3.00 1
B- CPVP 12.50 1 A2 -1.50 1 B2 -3.00 1 AB 5.75 1 A2B -12.25 1 AB2 7.75 1
Final Equation in Terms of Coded Factors: W = +37.00 +3.00 * A +12.50* B-1.50* A2 -3.00 * B2 +5.75* A * B -12.25* A2 * B +7.75 * A * B2
Department of Pharmaceutics, GCP, B’lore-27.
84
Results
Figure12: Perturbation plot showing effect of Concentration of SSG on wetting time.
DESIGN-EXPERT Plot
WT
X = A: SSG
Design Points
Actual FactorB: Cpvp = 8.75
5.00 8.75 12.50 16.25 20.00
17
25.25
33.5
41.75
50
A: SSG
WT
One Factor PlotWarning! Factor involved in an interaction.
22
Figure 13: Perturbation plot showing effect of Concentration of CPVP on wetting time.
DESIGN-EXPERT Plot
WT
X = B: Cpvp
Design Points
Actual FactorA: SSG = 12.50
5.00 6.88 8.75 10.63 12.50
16.1349
25.0674
34
42.9326
51.8651
B: Cpvp
WT
One Factor PlotWarning! Factor involved in an interaction.
22
Figure 14: 3-D graph showing combined effect of SSG and CPVP on wetting time.
DESIGN-EXPERT Plot
WTX = B: CpvpY = A: SSG
16.25
25.05
33.85
42.65
51.45
W
T
5.00
6.88
8.75
10.63
12.50
5.00
8.75
12.50
16.25
20.00
B: Cpvp A: SSG
Department of Pharmaceutics, GCP, B’lore-27.
85
Results
Response: DT Table 28: ANOVA Response Surface Cubic Model (Aliased)
Source Sum of Squares DF Mean F Value Prob >F Model 194.55 7 27.79 41.69 0.0055
A 12.50 1 12.50 18.75 0.0227 B 0.50 0.75 0.4502 - - A2 15.83 23.75 0.0165 - - B2 76.63 114.95 0.0017 - - AB 4.00 6.00 0.0917 - - A2B 1.33 2.00 0.2522 - - AB2 48.00 72.00 0.0034 - -
Residual 2.00 3 0.67 - - Lack of fit 0.000 1 0.000 0.000 1.0000
Pure 2.00 2 1.00 - - Cor Total 196.55 10 - - -
Table 29:Estimated Regression Coefficients
Factor Coefficient Estimate DF Standard Intercept 14.00 1 0.42 A- SSG -2.50 1 0.58
B- CPVP 0.50 1 0.58 A2 2.50 1 0.51 B2 5.50 1 0.51 AB 1.00 1 0.41 A2B 1.00 1 0.71 AB2 6.00 1 0.71
Department of Pharmaceutics, GCP, B’lore-27.
86
Results
Final Equation in Terms of Coded Factors:
DT =
+14.00
-2.50 * A
+0.50 * B
+2.50 * A2
+5.50 * B2
+1.00 * A * B
+1.00 * A2 * B
+6.00 * A * B2
Department of Pharmaceutics, GCP, B’lore-27.
87
Results
Figure 15: Perturbation plot showing effect of Concentration of SSG on DT.
DESIGN-EXPERT Plot
DT
X = A: SSG
Design Points
Actual FactorB: Cpvp = 8.75
5.00 8.75 12.50 16.25 20.00
12.3139
16.2354
20.1569
24.0785
28
A: SSG
DT
One Factor PlotWarning! Factor involved in an interaction.
2
2
2
2
Figure 16: Perturbation plot showing effect of Concentration of CPVP on DT.
DESIGN-EXPERT Plot
DT
X = B: Cpvp
Design Points
Actual FactorA: SSG = 12.50
5.00 6.88 8.75 10.63 12.50
13
16.75
20.5
24.25
28
B: Cpvp
DT
One Factor PlotWarning! Factor involved in an interaction.
2
2
2
2
Figure 17: 3-D graph showing combined effect of SSG and CPVP on disintegration time
DESIGN-EXPERT Plot
DTX = B: CpvpY = A: SSG
13.335
17.0012
20.6675
24.3338
28
D
T
5.00
6.88
8.75
10.63
12.50
5.00
8.75
12.50
16.25
20.00
B: Cpvp A: SSG
Department of Pharmaceutics, GCP, B’lore-27.
88
Results
Department of Pharmaceutics, GCP, B’lore-27.
89
Using the polynomial equations, the optimized formulations were obtained for the
response parameters. In the trial runs the optimized formulations were arrived using
numerical optimization in design expert 6.05 VERSION.
The data for the formulation variables, the response parameters and the constraints placed
on them are as follows.
Table 30: Optimized formula
Constraints
Upper Name Goal Lower
limit Upper limit
Lower weight
Upper weight
SSG is in range 5 20 1 3 Cpvp is in range 5 12.5 1 3 WT minimize 17 50 1 5 DT minimize 13 28 1 5
Table 31: Predicted solution of optimized formula
Solutions
Number SSG (mg)
CPVP (mg) WT (sec) DT (sec)
Desirability (R2)
1 5.13 12.50 16.9997 18.9582 0.776
Table 32: Pre-compression parameters of runs as per DOE. PARAMETERS R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11
Bulk Density (g/cc) 0.79 0.83 0.84 0.88 0.72 0.8 0.85 0.79 0.76 0.73 0.83Tapped Density (g /cc) 0.65 0.68 0.69 0.71 0.61 0.67 0.69 0.62 0.59 0.58 0.69
Angle of Repose (θ) 32.2 34.3 32.2 36.3 35.5 34.5 38.3 33.5 31.0 33.0 32.4Carr’s Index (%) 18.72 17.07 18.86 17.32 16.28 18.25 17.82 20.52 21.37 19.55 18.87
Table 33: Post compression parameters of runs as per DOE. .
PARAMETERS R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11
Hardness (Kg / cm2) 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.4 3.5 3.5 3.4 Friability (%) 0.4 0.32 0.16 0.16 0.16 0.16 0.24 0.32 0.24 0.24 0.32
Thickness (mm) 4.09 4.1 4.08 4.08 4.06 4.11 4.08 4.07 4.12 4.11 4.13Drug content (%) 98.21 100.51 98.98 99.56 99.21 98.91 99.49 99.87 100.01 100.12 98.54 Weight Variation 241 mg to 254 mg (IP limit: 231.25 mg to 268.75 mg)
90
Table 34: Comparison between Disintegration Time, Disintegration time in Oral cavity, and Wetting time.
PARAMETERS R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11
Average* 12.67 27.67 19.67 12.67 16.67 13.33 17.65 19.00 21.00 18.64 18.67DT in oral
cavity in (sec)
SEM n = 3 0.333 0.333 0.333 0.333 0.333 0.667 0.333 0.577 0.000 0.333 0.333
Average* 36.33 49.00 44.00 38.33 39.33 37.00 27.67 17.33 54.33 19.00 30.67Wetting time (sec) SEM
n = 3 0.667 0.557 0.577 0.667 0.667 0.000 0.333 0.333 0.333 0.577 0.333
Average* 17.67 29.33 25.33 17.33 19.67 16.33 21.67 23.67 26.33 21.67 2.67DT in (sec) SEM
n = 3 0.333 0.667 0.333 0.333 0.333 0.667 0.333 0.333 0.333 0.333 0.333
91
Figure 18: DISINTEGRATION PROFILE OF RUNS AS PER DOE.
0
10
20
30
40
50
60
R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11
Dis
inte
grat
ion
time
( sec
s)
DT WT DTO92
81
Results
Department of Pharmaceutics, GCP, B’lore-27.
Results
In Vitro Release rate profile of Runs as per DOE in simulated gastric fluid (pH 1.2) after 5 and 20 mins
Table No. 35
Formulations Absorbance Conc. (mcg /ml)
Conc. (mg / 5ml)
Conc. (mg/900ml) CLA CDR
%CDR after 5
mins R1 0.370 9.525 0.048 8.573 0 8.573 87.30 R2 0.361 9.284 0.046 8.356 0 8.356 83.14 R3 0.367 9.445 0.047 8.501 0 8.501 85.95 R4 0.368 9.472 0.047 8.525 0 8.525 86.81 R5 0.365 9.391 0.047 8.452 0 8.452 85.98 R6 0.368 9.472 0.047 8.525 0 8.525 86.54 R7 0.368 9.472 0.047 8.525 0 8.525 85.68 R8 0.365 9.391 0.047 8.452 0 8.452 84.95 R9 0.355 9.123 0.046 8.211 0 8.211 84.74 R10 0.379 9.767 0.049 8.790 0 8.790 89.79 R11 0.368 9.472 0.047 8.525 0 8.525 86.54
Table No. 36
Formulations Absorbance Conc. (mcg /ml)
Conc. (mg / 5ml)
Conc. (mg/900ml) CLA CDR
%CDR after 20
mins R1 0.395 10.196 0.051 9.176 0.0967 9.273 94.43
R2 0.405 10.464 0.052 9.417 0.0974 9.515 94.67
R3 0.405 10.464 0.052 9.417 0.0967 9.514 96.20
R4 0.393 10.142 0.051 9.128 0.0965 9.224 93.93
R5 0.403 10.410 0.052 9.369 0.0961 9.465 96.29
R6 0.409 10.571 0.053 9.514 0.0965 9.610 97.57
R7 0.398 10.276 0.051 9.249 0.0970 9.346 93.92
R8 0.405 10.464 0.052 9.417 0.0974 9.515 95.63
R9 0.382 9.847 0.049 8.862 0.0938 8.956 92.43
R10 0.412 10.651 0.053 9.586 0.0990 9.685 98.93
R11 0.409 10.571 0.053 9.514 0.0965 9.610 97.57
Department of Pharmaceutics, GCP, B’lore-27 93
Results
Figure 19: Dissolution Profile of runs as per DOE in Simulated Gastric Fluid
(pH 1.2) after 5 and 20 minutes.
0
20
80
60
40
100
R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11
%C
DR
After 5 mins After 20 mins
Department of Pharmaceutics, GCP, B’lore-27. 95
Results
Table 37: Composition of the optimized formula.
*INGREDIENTS R
Metoclopramide HCl 10
Avicel PH200 177.87
Cross Povidone 12.5
Sodium Starch Glycolate 5.13
Pregelatinized Starch 31.5
Aspartame 5
Magnesium Stearate 4
Talc 4
TOTAL 250
*All the quantities expressed are in mg / tablet.
Table 38: Pre-compression parameters of optimized formulation.
PARAMETERS R Bulk Density (g/cc) 0.88
Tapped Density (g /cc) 0.71 Angle of Repose (θ) 36.3
Carr’s Index (%) 17.32
Table 39: Post compression parameters of optimized formulation.
Department of Pharmaceutics, GCP, B’lore-27. 96
PARAMETERS R Hardness (Kg / cm2) 3.5
Friability (%) 0.16 Thickness (mm) 4.08 Drug content (%) 99.56 Weight variation 240 –253mg
Results
Table 40: Comparison between Disintegration Time, Disintegration time in Oral cavity,
and Wetting time.
PARAMETERS R
Average* 12.67 DT in oral
cavity in (sec)
SEM (±) n = 3 0.333
Average* 38.33 Wetting time (sec) SEM (±)
n = 3 0.667
Average* 17.33 DT in (sec) SEM (±)
n = 3 0.333
Table 41: Dissolution profile of runs as per DOE.
Time (minutes) Absorbance Conc.
(mcg /ml)Conc.
(mg / 5ml)Conc.
(mg/900ml) CLA CDR
%CDR
0 0 0 0 0 0 0 0
5 0.365 9.391 0.047 8.452 0 8.452 84.95
10 0.391 10.088 0.050 9.080 0.0470 9.127 91.72
15 0.405 10.464 0.052 9.417 0.0974 9.515 95.63
20 0.389 10.035 0.050 9.031 0.1497 9.181 92.27
Department of Pharmaceutics, GCP, B’lore-27. 97
Results
Figure 20: Dissolution profile of optimized formulation.
0
20
40
60
80
100
120
0 5 10 15 20 25
Time ( in minutes)
% C
DR
Department of Pharmaceutics, GCP, B’lore-27. 98
Results
Stability Studies
Table 42: Stability data of optimized formulation stored at 250C / 60%RH
Optimized formulation Time in days
PA %DC
0 +++ 100.01
30 +++ 100.01
60 ++ 99.90
PA: Physical appearance +++: Same as on ‘0’ day
%DC: Percentage Drug content ++: Slight change in appearance
Table 43: Stability data of optimized formulation stored at 40o C / 75 % RH
Optimized formulation Time in days
PA %DC
0 +++ 100.01
30 +++ 100.01
60 ++ 99.90
PA: Physical appearance +++: Same as on ‘0’ day
%DC: Percentage Drug content ++: Slight change in appearance
Department of Pharmaceutics, GCP, B’lore-27. 99
Results
Department of Pharmaceutics, GCP, B’lore-27. 100
Discussion
DISCUSSIONS
The present study was carried out to develop rapidly disintegrating tablets of
Metoclopramide Hydrochloride by direct compression method. Hence it was necessary to
find suitable excipients with good compactability and disintegrating ability.
Preformulation
In the preformulation study, it was found that the estimation of Metoclopramide
Hydrochloride by UV spectrophotometric method at λmax 273.0 nm in 0.1N Hydrochloric
acid had good reproducibility and this method was used in the study. The correlation
coefficient for the standard curve was found to be closer to 1, at the concentration range,
2- 25 mcg/ml.. The regression equation generated was y = 0.0387x + 0.0063.
Drug-excipient compatibility studies
Thin Layer Chromatography was carried out to check for the possible drug-
excipient interaction. The Rf values of the drug and excipients used in the study were
similar. This established that the drug (Metoclopramide Hydrochloride) and all the
excipients used in the study showed no interaction between them and indicated that they
were compatible with each other. The photograph and Rf values are given in page no.
(Fig 5, Table No 2).
Department of Pharmaceutics, GCP, B’lore-27
100
Discussion
Formulation and Evaluation of rapidly disintegrating tablets
In direct compression method, Mannitol, Dicalcium phosphate, and Avicel PH
200 were selected as directly compressible diluents25. Crospovidone, Croscarmellose
sodium, Sodium starch glycolate and Low-substituted Hydroxypropyl cellulose were
used as disintegrants. In all the formulations, Pregelatinized starch was used as a binding
agent to attain hardness. Aspartame was used as a sweetening agent. Magnesium
stearate and talc were used as lubricant and glidant respectively.
Precompression parameters
The precompression parameters for the formulations, formulated by direct
compression method are as given below:
Table 44: Comparison of Precompression parameters of all the formulations.
Formulations
Parameters Mannitol (M1-M12)
DCP (E1-E12)
Avicel PH 200 (A1-A12)
Bulk Density (g/cc) 0.61 – 0.69 0.64 – 0.73 0.49 – 0.63 Tapped Density (g / cc) 0.52 - 0.6 0.49 – 0.58 0.39 – 0.49
Carr’s Index (%) 8.20 – 20.0 18.31 – 25.0 20.41 – 26.98
Angle of Repose (θ) 320 - 380 320 - 390 300 - 390
The Carr’s Index values indicate that-
1. Mannitol powder mixtures showed good flow properties
2. Dicalcium Phosphate powder mixtures showed fair flow properties
Department of Pharmaceutics, GCP, B’lore-27
101
Discussion
3. Avicel PH 200 powder mixtures showed poor flow properties for the ingredients used
in the study.
The Angle of repose values indicate that all the formulations showed acceptable flow
properties.
Physical properties of tablets
Hardness
The hardness was determined for all the formulations and the results were as
follows.
Table 45: Comparison of Hardness of all the formulations.
Formulations Hardness (kg/ cm2)
Mannitol 4.0
DCP 3.5
Avicel PH 200 4.0
The hardness of all the formulations was kept at 3.0 ± 1 kg / cm2 to compare the
disintegration time between the formulations.
Friability
The percentage friability of all the formulations were found to be not more than
0.6 %, which is well within the 1 % limit. The results of friability indicated that the
tablets were mechanically stable.
Department of Pharmaceutics, GCP, B’lore-27
102
Discussion
Weight variation
The weights of the tablets were between 239.0 mg to 258.0 mg. As the weight of
tablets was 250 mg, the acceptable weight variation range is between 232.5 mg to 267.5
mg (± 7.5 %). Hence all the tablet formulations were within the pharmacoepial limits.
Assay
The percentage drug content of all the tablets was found to be between 94.37 %
and 100.51 % of Metaclopramide Hydrochloride, which was within the acceptable limits.
Disintegration time as per IP, Wetting time and Disintegration time in Oral cavity was
determined for all the formulations.
Disintegration Time as per IP
Disintegration time as per IP, for all the formulations was found to be within 77
seconds, which was well within IP limit. (IP limit is 180 seconds)
Formulations with Crospovidone and Sodium starch glycolate as disintegrants
exhibited quicker disintegration of tablets than compared to Croscarmellose sodium &
low-substituted Hydroxypropyl cellulose. It indicated that amongst the disintegrants used
Sodium starch glycolate and Crospovidone were better disintegrants to formulate rapidly
disintegrating tablets by direct compression method for Metaclopramide Hydrochloride
than Croscarmellose sodium and L-HPC. This can be attributed to the extent of water
uptake and consequently the strong swelling power of these disintegrants caused
Department of Pharmaceutics, GCP, B’lore-27
103
Discussion
sufficient hydrodynamic pressure to induce complete disintegration. These disintegrants
swell to a large extent when they come in contact with water to disintegrate tablets and
has a fibrous nature that allows intraparticulate, as well as extraparticulate, wicking of
water even at low concentration levels (10%).
Wetting time
Wetting time, for all the formulations was found to be within 59 seconds.
Formulations with Crospovidone and Sodium starch glycolate as disintegrants exhibited
quicker Wetting time of tablets than compared to Croscarmellose sodium & Low-
substituted Hydroxypropyl cellulose. It indicated that amongst the disintegrants used,
Sodium starch glycolate and Crospovidone were better disintegrants to formulate rapidly
disintegrating tablets by direct compression for Metaclopramide hydrochloride than
Croscarmellose sodium and L-HPC. This may be due to the low porosities of these
disintegrants.
Disintegration Time in Oral Cavity
It was observed that all the tablets disintegrated in oral cavity within 69 seconds.
• Tablets prepared with Avicel PH 200 as diluent disintegrated in oral cavity
between 19.33 seconds and 27 seconds.
• Tablets prepared with Dicalcium Phosphate as diluent disintegrated in oral cavity
between 32 seconds and 59.67 seconds.
• It was found that tablets prepared with Mannitol as diluent took longer time (40
second to 70.67 seconds) to disintegrate in oral cavity than other diluents used in
Department of Pharmaceutics, GCP, B’lore-27
104
Discussion
the study. The disintegration time in oral cavity in case of Mannitol formulations
was between 40 second to 70.67 seconds.
Rapid disintegration of tablets containing Avicel PH 200 as diluent was attributed to the
penetration of water into the hydrophilic tablet matrix by means of capillary action of the
pores and by subsequent disruption of the hydrogen bonds24.
Dissolution rate study
The dissolution study was carried out using 900 ml of simulated gastric fluid as
dissolution medium at 50 rpm at 370C ± 0.50C in USP Type II apparatus. All the
formulations showed rapid dissolution rate and the percentage cumulative drug release
(%CDR) after 5 minutes was more than 81.64 % and complete dissolution was achieved
within 20 minutes.
Optimized Formulations
Using the polynomial equations, the optimized formulations were obtained for the
response parameters. In the trial runs, the optimized formulations were arrived using
numerical optimization in design expert 6.05 VERSION.
Rapidly disintegrating tablets are gaining importance as new drug delivery systems.
These dosage forms dissolve or disintegrate in oral cavity without the need of water or
chewing. A number of superdisintegrants are available in the market, which markedly
improve tablet disintegration by swelling and exerting sufficient pressure in the tablet to
break it apart into small segments. Selection of an appropriate superdisintegrant depends
up on its concentration in decreasing the DT of a tablet. Hence, an optimization technique
Department of Pharmaceutics, GCP, B’lore-27
105
Discussion
was adapted. The tablets were prepared following 32 full factorial designs. For rapid drug
dissolution, the carrier material should be highly soluble in the dissolution medium;
hence, lactose was chosen as carrier material, which is highly soluble. Crospovidone, an
effective disintegrant and also has bioadhesive property is expected to prolong the
residence time of the drug at the oral mucosa and their by increasing the absorption. In
this study, the effect of formulation variables: the amount of SSG and crospovidone was
chosen as independent variables. The dependent (response) variables include wetting
time and DT. For the generation of polynomial models, only coefficients found to be
significant (p<0.05) were used.
Effect of formulation variables on WT
The cubic model for Y1 (WT) was found to be significant with an F value of 20.37 (p<
0.0156).
Y1 = 37.00 + 12.50 X2 + 5.75 X1X2 -12.25 X12 X2
+ 7.75 X1X22
In this case, only factor X2 and its interaction with X1 and X2 were found to be
significant. Increase in the amount of crospovidone, increases the WT. The relation ship
between the variables was further elucidated using Response surface plot (Figure 10).
At lower level of X1 and X2, the WT time was found to be 27.25 seconds and as the
concentration of CPVP is increased from low to higher level the WT decreased to 16.25
seconds. Similarly, if the concentration of CPVP was increased from low to higher value
the WT increased from 37.25 to 49.25 by keeping the concentration of SSG at higher
level. High value of WT in case of crospovidone may be due to it’s binding property.
Department of Pharmaceutics, GCP, B’lore-27
106
Discussion
Effect of formulation variables on disintegration time
The Model F-value of 41.69 implies the model is significant. There is only a 0.55%
chance that a "Model F-Value" this large could occur due to noise.
Values of "Prob > F" less than 0.0500 indicate model terms are significant.
In this case A, A2, B2, AB2 are significant model terms.
Y3 = 14.00 – 2.50 X1 + 2.50 X12 + 2.50 X2
2 + 6.00 X1X22
The coefficient X1 shows negative sign; on increasing the concentration of crospovidone
a decrease in DT is observed. High concentration of crospovidone leads to swelling and
water uptake, which subsequently facilitate disintegration. The interaction effect between
X1 and X2 are shown in Response surface plot (Figure 7). At low concentration of
crospovidone and if 5 mg of MCC were used, then the DT were found to be 18 sec and
19 seconds when the concentration of Crospovidone is increased. Similarly the DT
decreases from 23.00 seconds to 28.00 seconds, if 20 mg of SSG were used and
crospovidone was increased from 5 to 12.50 mg. The results conveyed us that, factor X2
has significant effect on DT than that of X1. Presence of high amount of crospovidone
wicking is facilitated and known to have an optimum concentration regarding
disintegrating time.
The data of pure error and lack of fit are summarized in ANOVA table, which can
provide a mean response and an estimate of pure experimental uncertainty. The residuals
are the difference in the observed and predicted value. Since, the computed F values were
respectively less than the critical F value, which denotes non-significance of lack of fit.
Department of Pharmaceutics, GCP, B’lore-27
107
Discussion
A numerical optimization technique by the desirability approach was used to
generate the optimum setting for the formulation using minimizing WT and DT.
The optimized formulations were prepared using the various criteria as mentioned in the
earlier section and the formulations were evaluated for the various responses.
Optimization results therefore obtained were included in the following table.
Table 46: Comparison chart of predicted and actual values for optimized formulation.
Formulation WT DT
Predicted Actual Predicted Actual Opt form
16.997 17.20 18.958 19.10
Stability studies
The formulations had a residual drug content of more than 97% after 2 months
when stored at 25oC / 60% RH and 40oC / 75%RH. These results indicated that the
selected formulations were stable. Also, the aged samples showed no change in the
Physical appearance, hardness or drug content.
The drug excipient compatibility studies indicated that there was no change in the Rf
values of the drug and the excipient.
Department of Pharmaceutics, GCP, B’lore-27
108
Conclusion
CONCLUSION
In the present work, an attempt was made to develop rapidly disintegrating tablets
of Metoclopramide Hydrochloride
From the study conducted, the following conclusions are drawn:
Amongst the various combinations of diluents and disintegrants used in the study,
tablets that were formulated (direct compression) using Crospovidone and Sodium starch
glycolate exhibited quicker disintegration of tablets than compared to those of L-HPC
and Crosscarmellose sodium.
Based on the optimization results it is concluded that the objective of
formulating Rapidly Disintegrating Tablets containing Metoclopramide
Hydrochloride has been achieved with success.
SCOPE FOR FURTHER STUDIES
1. The so developed formula can be adopted to formulate Rapidly
Disintegrating Tablets containing highly water soluble drugs, where
desired action is required in short time. Example: Salbutamol and
Terbutaline Sulphate for the treatment of Bronchitis.
2. The work can be extended to invivo studies by using Rabbit as animal
model and carry out the invitro and invivo Correlation studies.
3. The work can be extended to study the effect of compression pressure,
shape and diameter of the tablet and size of particles (based on mesh
screen).
Department of Pharmaceutics, GCP, B’lore-27 109
Summary
SUMMARY
The present study is an attempt to select the best possible diluent - disintegrant
combination to formulate rapidly disintegrating tablets of Metoclopramide
Hydrochloride, which disintegrates in matter of seconds in the oral cavity, thereby
reducing the time of onset of pharmacological action.
Mannitol, Dicalcium phosphate, and Avicel PH 200 were selected as directly
compressible diluents. Crospovidone, Croscarmellose sodium, Sodium starch glycolate
and Low-substituted Hydroxypropyl cellulose were used as disintegrants. In all the
formulations, Pregelatinized starch was used as a binding agent to attain hardness.
Aspartame was used as a sweetening agent. Magnesium stearate and talc were used as
lubricant and glidant respectively.
The results of the drug – excipient compatibility studies revealed that there was
no chemical interaction between the pure drug and excipients.
Direct compression method was employed to formulate the tablets, because of its
cost effectiveness and due to reduced number of manufacturing steps.
The precompression parameters like bulk density, tapped density, Carr’s ‘index
and angle of repose were determined. All the 36 formulations showed acceptable flow
properties.
The postcompression parameters like the hardness, thickness, friability and weight
variation, disintegration time, wetting time, disintegration time in oral cavity and Invitro
release were carried out and the values were found to be within IP limits.
Department of Pharmaceutics, GCP, B’lore-27
110
Summary
The percentage drug content of all the tablets was found to be between 94.37 %
and 100.51 % of Metaclopramide hydrochloride, which was within the acceptable limits.
From the data obtained, it is observed that Formulations with Crospovidone and
Sodium starch glycolate as disintegrants exhibited quicker disintegration and wetting
time of tablets than compared to Croscarmellose sodium & low-substituted
Hydroxypropyl cellulose. It indicated that amongst the disintegrants used Sodium starch
glycolate and Crospovidone were better disintegrants to formulate rapidly disintegrating
tablets by direct compression method for Metaclopramide hydrochloride.
Based on the preliminary experiment Crospovidone and Sodium starch
glycolate were found to be the best disintegrating agents in the formulation of
Rapidly disintegrating tablets. But, appropriate amount of SSG and CPVP were found
to affect the DT. Hence, a 32 factorial design of experiment was performed by which
the amount of Crospovidone and Sodium starch glycolate was considered as
independent variables. As per the DOE totally 11 possible combinations were
performed with3 centre points to find out the lack of fit and errors due to experiments.
The response parameters were fitted to cubic model to access the effect of
formulation variables. Based on the polynomial equation and response surface plots,
the optimized formulation was arrived by using desirability function. The so
developed optimized formulation was further challenged with experimentation and
was found that, the predicted values were in close agreement with the actual values,
indicating the validation of the model.
Department of Pharmaceutics, GCP, B’lore-27
111
Bibliography
BIBLIOGRAPHY
1. Kuchekar B S, Bhise S B, Armugam V. Design of fast dissolving tablets. Ind. J.
Pharm. Edu. 2001; 35 (4): 150-152.
2. Reddy L. H, Ghosh B, Rajneesh. Fast dissolving drug delivery systems: A review
of the literature. Ind. J. Pharm. Sci. 2002; (7,8): 331-336.
3. Luca Dobetti. Fast- Melting tablets: Developments and Technologies.
Pharmaceutical Technology 2001: 11.
4. Schwartz B J, Connor R E. Optimization technique in pharmaceutical
formulations and processing. Modern Pharmaceutics. 3rd edition. Marcel Dekker
Inc. New York; 1996.
5. Bolton S. Pharmaceutical statistics- Practical and clinical applications. 3rd edition.
Marcel Dekker Inc. New York; 1997.
6. Mark Anderson, Sharikraber. Two level full factorial tutorials. Design expert
Software, Version 6.05 users guide. Inc., New York.
7. Sean C Sweetman. Martindale: The Complete Drug reference. 33rd Edition
London: The Pharmaceutical press; 2001.
8. Ainley Wade, Paul J Weller. Handbook of Pharmaceutical Excipients:
Monographs. London: The Pharmaceutical press; 2000.
9. Yunxia Bi, Hisakazu Sunada, Yorinobu yonezaywa, Kazumi Danjo, Akinobo
Otsuka. Preparation and evaluation of a compressed tablet rapidly disintegrating
in the oral cavity. Chem. Pharm. Bull. 1996; 44(11) 2121-2127.
Department of Pharmaceutics, GCP, B’lore-27. 112
Bibliography
10. Y. X. Bi, H. Sunada, Yonezawa Y, Danjo K. Evaluation of rapidly disintegrating
tablets prepared by direct compression method. Drug development and Industrial
pharmacy 1999; 25(5): 571-581.
11. Scheirmeier S, Peter Christian Schmidt. Fast dispersible Ibuprofen tablets.
Eur J Pharm. Sci. 2002; 15: 295-305.
12. Hisakadsu Sunada, Yunxia Bi. Preparation, Evaluation and optimization of
rapidly disintegrating tablets. Powder technology 2002; 122: 188-198.
13. Akihiko Ito, Masayasu Sughihara. Development of oral dosage form for elderly
patients: use of agar as a base of rapidly disintegrating oral tablets. Chem. Pharm.
Bull. 1996; 44(11) 2132-2136.
14. Ishikawa T, Watanabe Y, Utoguchi N, Matsumoto M. Preparation and evaluation
of tablets rapidly disintegrating in saliva containing bitter taste mask granules by
the compression method. Chem. Pharm. Bull.1999; 47 (10): 1451-1454..
15. Yoshiteru Watanabe, Koizumi K, Kiriyama M, Matsumato Y. New compressed
tablets Rapidly Disintegrating in saliva in the mouth using crystalline cellulose as
Disintegrant. Biol. Pharm. Bull. 1995; 18 (9): 1308-1310.
16. Shenoy V, Agarwal S, Pandey S. Optimizing fast dissolving dosage form of
Diclofenac sodium by rapidly disintegrating agents. Ind. J. Pharm. Sci. 2003:
197-201.
17. Chowdary KPPR, Rama Rao N. Formulation and evaluation of Piroxicam tablets
with Piroxicam-Pregelatinized starch dispersions. Indian Drugs 2000; 37 (2),
99-101.
Department of Pharmaceutics, GCP, B’lore-27. 113
Bibliography
18. Chowdary KPR, Sujatha Rao. Formulation and evaluation of dispersible tablets
of poorly soluble drugs. Ind. J. Pharm. Sci. 1991; Jan-Feb: 31-32.
19. Harish Rao, Aroor AR. Florimetric estimation of Metoclopramide in dosage
forms. Indian drugs 1991; 28(4): 195-196.
20. Emmanuel J and Roy Mathew. Colorimetric estimation of Metoclopramide
Hydrochloride in pharmaceutical formulations. Eastern Pharmacist 1984; 27:129.
21. Bhatkar RG and Chondkar SK. Spectrophotometric determination of
Metoclopramide Hydrochloride. Eastern Pharmacist 1981; 24:125.
22. Kamalapurkar OS and Chudasama JJ . Spectrophotometric estimation of
Metoclopramide Hydrochloride and its dosage forms. Indian drugs 1983: 298-
299.
23. British Pharmacoepia. London: Her Majesty’s Stationary Office; 2003.
24. Jesusa Joyce. Optimization of a new filler/ binder for direct compression using
central composite design. Drug dev. Ind. Pharm 1997; 23(10): 945-950.
25. Renoux R. Experimentally designed optimization of direct compression tablets.
Drug dev. Ind. Pharm 1996; 22(2): 103-109.
26. Lipp R, Heimann. Statistical approach to optimization of drying conditions for
transdermal delivery system. Drug dev. Ind. Pharm 1996; 22(4): 343-348.
27. Lalla JK, Bhat SU. Non- pareil seed: 23! Factorial approach to optimization of
coating for pellet preparation: coating pan vs. dish pelletizer. Indian drugs 1992;
29: 527-536.
28. Church HR. Optimization of Sotalol floating and Bioadhesive adhesive release
tablet formulations. Drug dev. Ind. Pharm 1995; 21(15): 1725-1747.
Department of Pharmaceutics, GCP, B’lore-27. 114
Bibliography
29. Indian Pharmacoepia. Govt. Of India Ministry of Health; 1996.
30. USP 24: NF 19. Asian Edition. United states Pharmacoepia convention Inc.
Department of Pharmaceutics, GCP, B’lore-27. 115